Merck & Co., Inc. (NYSE: MRK)

Investor-Grade Deep Dive Research Report

Report Date: March 11, 2026
Prepared by: Ada Cockpit Research
Company: Merck & Co., Inc. (known as MSD outside the United States and Canada)
Stock Ticker: NYSE: MRK

Executive Summary

Company Overview

Merck & Co., Inc. is a global research-driven pharmaceutical company headquartered in Rahway, New Jersey, United States. Founded in 1891 as a U.S. subsidiary of the German Merck Group, the company became independent in 1917 and has evolved into one of the world's leading pharmaceutical companies.[1][2] As of December 31, 2025, Merck employed approximately **75,000 people** globally, unchanged from 2024.[3][4]

Key Financial Metrics (Full-Year 2025)

- **Worldwide Sales:** $65.0 billion (+1% nominal, +2% excluding foreign exchange)[5][6]
- **GAAP Net Income:** $18.3 billion (preliminary, +7% from 2024's $17.1 billion)[7]
- **GAAP EPS:** $7.28 (+8% year-over-year)[5][7]
- **Non-GAAP EPS:** $8.98[7]
- **Operating Expenses:** $26.5 billion (-8% from 2024)[8]
- **EBITDA Margin:** Estimated at 28-30% based on quarterly figures ($7.74B Q1, $8.39B Q3)[8][9]
- **R&D Investment:** $15.8 billion (~24% of revenue)[10]
- **Market Capitalization:** $289-302 billion (early March 2026)[11][12]
- **Enterprise Value:** $342 billion (March 2026)[12]

Strategic Position and Growth Trajectory

Merck's strategic position is dominated by **Keytruda (pembrolizumab)**, the world's leading oncology franchise, which generated $31.7 billion in 2025 sales, representing approximately 49% of total company revenue.[13][14] The company faces a critical patent cliff with Keytruda's primary U.S. compound patent expiring in December 2028, though additional patents and a new subcutaneous formulation (Keytruda QLEX) may extend market exclusivity.[15][16]

To counter this looming challenge, Merck has aggressively pursued strategic acquisitions and built a pipeline targeting over **$70 billion in non-risk-adjusted commercial opportunities** by the mid-2030s, more than double Keytruda's current peak sales.[17][18] The company has restructured its Human Health business into two units: an Oncology Business Unit led by Jannie Oosthuizen, and a Specialty, Pharma & Infectious Diseases Business Unit led by Brian Foard.[19][20]

2026-2028 Targets and Medium-Term Outlook

- **2026 Guidance:** Revenue of $65.5-67.0 billion (+1-3% growth); Non-GAAP EPS of $5.00-5.15 (midpoint $5.08)[21][22]
- **Growth Drivers:** New launches including Winrevair ($1.4B in 2025), Capvaxive ($759M), Ohtuvayre ($178M Q4), and Welireg ($509M)[23][24][25]
- **Pipeline Strategy:** 20 late-stage assets with blockbuster potential, supported by major acquisitions:

- Verona Pharma ($10B, Oct 2025) for Ohtuvayre (COPD)[26]
- Prometheus Biosciences ($10.8B, 2023) for MK-7240 (IBD)[27][28]
- Cidara Therapeutics ($9.2B, Jan 2026) for CD388 (influenza prevention)[29][30]
- EyeBio (up to $3B, 2024) for Restoret (wet AMD)[31][32]
- Daiichi Sankyo ADC collaboration (up to $22B)[33][34]

Key Risks

1. **Keytruda Patent Cliff (2028):** Primary revenue driver faces loss of exclusivity
2. **Gardasil Decline:** China sales collapsed 39% in 2025; patent expiration 2028-2038[35][36]
3. **Januvia Generic Entry:** Mid-2026 generic competition for $2.9B diabetes franchise[37]
4. **IRA Pricing Pressure:** Medicare drug price negotiation may impact Keytruda from 2029[38]
5. **Pipeline Execution:** Heavy reliance on M&A to fill post-Keytruda revenue gap

Forward-Looking Statement

This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section.

---

1. Company History

Founding and Early Years (1891-1950)

Merck & Co. traces its origins to **1668** when Friedrich Jacob Merck acquired the Angel Pharmacy in Darmstadt, Germany, establishing what would become Merck KGaA.[1][39] The American subsidiary was founded on **January 1, 1891** in New York City by George Merck and Theodore Weicker to distribute fine chemicals in the United States.[1][39][40]

In **1903**, Merck began manufacturing operations in Rahway, New Jersey.[1] During **World War I (1917)**, the U.S. government seized the American subsidiary's assets under the Trading with the Enemy Act, making Merck & Co. an independent American company, permanently separated from its German parent.[1][2][39][40]

Mid-Century Expansion (1927-1980)

- **1927:** Merged with Powers-Weightman-Rosengarten Company, expanding manufacturing capabilities[39][40]
- **1933:** Established Merck Research Laboratory in Rahway, New Jersey[1][2][39]
- **1943:** Funded discovery of streptomycin, the first effective tuberculosis treatment[1][2]
- **1953:** Merged with Sharp & Dohme, Inc., forming Merck Sharp & Dohme (MSD) as the international brand, becoming the largest U.S. drugmaker at the time[1][2][39][40]
- **1979:** Developed lovastatin (Mevacor), the first statin drug for cholesterol reduction[39][40]

Modern Era: Consolidation and Transformation (1990-2020)

- **1993:** Acquired Medco Managed Care (pharmacy benefit manager), later spun off in 2003[40]
- **2006:** Launched Gardasil, the first HPV vaccine[1][39]
- **2007:** Spun off Organon BioSciences (women's health) and sold it to Schering-Plough for $14 billion[40]
- **2009:** Acquired Schering-Plough for **$41 billion**, one of pharma's largest deals, integrating vaccines, biologics, and animal health assets[1][40]
- **2013:** Spun off Zoetis (animal health from Schering-Plough acquisition)
- **2014:** FDA approved Keytruda (pembrolizumab) for melanoma, beginning its transformation into the world's top-selling drug[1][39]

Leadership Transitions

- **2011-2021: Kenneth C. Frazier** served as CEO, becoming the first Black CEO of a major U.S. or European pharmaceutical company. He led the company through the Schering-Plough integration and Keytruda's rise, overseeing growth from $48.0B revenue (2011) to $48.7B (2021, post-Organon spinoff).[41][42][43]
- February 2021: Announced retirement plan
- June 30, 2021: Stepped down as CEO
- July 1, 2021 - November 30, 2022: Served as Executive Chairman
- **July 1, 2021 - Present: Robert M. Davis** became CEO and President. Davis joined Merck in 2014 as CFO, expanded his role to EVP of Global Services and CFO in 2016, and became President in April 2021 before assuming the CEO role.[44][45][46]
- December 1, 2022: Also assumed role of Chairman of the Board

Recent Strategic Acquisitions (2021-2026)

- **2021:** Acceleron Pharma ($11.5B) - acquired sotatercept (Winrevair) for pulmonary arterial hypertension[47]
- **2021:** Spun off Organon (biosimilars, women's health, legacy brands) as independent company
- **2023:** Prometheus Biosciences ($10.8B) - MK-7240 for inflammatory bowel disease[27][28]
- **2024:** EyeBio (up to $3B) - Restoret for wet age-related macular degeneration[31][32]
- **2025:** Verona Pharma ($10B, closed Oct 7) - Ohtuvayre (ensifentrine) for COPD[26][48]
- **2026:** Cidara Therapeutics ($9.2B, closed Jan 7) - CD388 influenza prevention[29][30]

This aggressive M&A strategy reflects Merck's "portfolio transformation" approach to diversify beyond Keytruda ahead of its 2028 patent expiration.

---

2. Ownership Structure

Public Company Status

Merck & Co., Inc. is a publicly traded company listed on the New York Stock Exchange under ticker symbol **MRK**. The company has a broad institutional and retail shareholder base.

Major Institutional Shareholders (2025)

Merck has **4,648 institutional owners** holding a total of **2,186,081,220 shares**.[49] The largest institutional shareholders include:

Institution	Ownership Type	Notes
Vanguard Group Inc	Passive Index	Largest institutional holder
BlackRock, Inc.	Mixed Active/Passive	Second largest holder
State Street Corp	Passive Index	Third largest holder
Wellington Management Group LLP	Active	Significant active manager
Geode Capital Management LLC	Passive	Index funds
Charles Schwab Investment Management Inc	Mixed	Retail brokerage funds
Morgan Stanley	Mixed	Active and passive strategies
Fmr LLC (Fidelity)	Active	Active management

Specific Vanguard funds with major positions include VTSMX (Total Stock Market Index Fund) and VFINX (500 Index Fund).[49]

The average institutional portfolio allocation to Merck stock is **0.49%**, with a +1.09% change in holdings in the most recent quarter, indicating modest accumulation.[49]

Board of Directors Composition

Merck's Board of Directors comprises the following members (as of 2025):[50][51]

1. **Robert M. Davis** - Chairman, CEO, and President
2. **Douglas M. Baker, Jr.** - Independent Director
3. **Mary Ellen Coe** - Independent Director
4. **Pamela J. Craig** - Independent Director
5. **Thomas H. Glocer** - Independent Director
6. **Surendralal L. Karsanbhai** - Independent Director
7. **Risa J. Lavizzo-Mourey, M.D.** - Independent Director
8. **Stephen L. Mayo, Ph.D.** - Independent Director
9. **Paul B. Rothman, M.D.** - Independent Director
10. **Patricia F. Russo** - Independent Director
11. **Christine E. Seidman, M.D.** - Independent Director
12. **Inge G. Thulin** - Independent Director
13. **Kathy J. Warden** - Independent Director

The board maintains strong independent oversight with only the CEO serving as a management director. No major governance red flags or concentrated control structures are evident in public filings.

Data Gaps

- Exact percentage stakes for individual institutional investors are not disclosed in available sources
- Insider ownership percentages (executives and board members) are not specified in search results
- No significant activist investor positions were identified in available data

---

3. Leadership / C-Suite

Chairman, President & Chief Executive Officer

Robert M. Davis
CEO: July 1, 2021 - Present; Chairman: December 1, 2022 - Present

- **Age:** 58 (as of 2025)
- **Education:**
- B.S. in Finance, Miami University
- MBA, Kellogg School of Management, Northwestern University (1993)
- J.D., Northwestern University School of Law (1998)[44][45][46]
- **Career at Merck:**
- 2014-2016: Chief Financial Officer and Executive Vice President
- 2016-2021: EVP, Global Services, and CFO (expanded role)
- April 2021-June 2021: President
- July 2021-Present: CEO and President
- December 2022-Present: Also Chairman of the Board
- **Pre-Merck Experience:**

- 2004-2014: Baxter International - Corporate VP & President Medical Products; President Renal Business; CFO & Treasurer
- ~1990-2004: Eli Lilly & Co. - Various positions (14 years)[44][45][46]
- **Board Memberships:** Duke Energy Corp. (Finance/Risk Committee Chair); Project Hope (nonprofit)
- **Personal:** Grew up in small farming town; motivated by father's death from lung cancer[52]

Executive Vice President & Chief Financial Officer

Caroline A. Litchfield
CFO: April 1, 2021 - Present

- **Education:** B.S. in Mathematics, University of Leicester; Fellow, Chartered Institute of Management Accountants[53][54]
- **Career at Merck (joined 1990):**
- 1990-2009: Various roles in UK business and international finance
- 2009-2014: Vice President, Finance Lead for Emerging Markets (post-Schering-Plough merger integration)
- 2014-2018: Finance lead for Human Health division (~100 markets globally)
- 2018-2021: Senior Vice President and Treasurer
- April 2021-Present: Executive Vice President and Chief Financial Officer[53][54][55]
- **2024 Compensation:** $1,170,000 salary[56]

Executive Vice President & President, Merck Research Laboratories

Dean Y. Li, M.D., Ph.D.
President, MRL: January 2021 - Present

- **Education:** B.S. in Chemistry, University of Chicago; M.D. and Ph.D., Washington University School of Medicine[57]
- **Pre-Merck Academic Career:**
- University of Utah: H.A. & Edna Benning Professor of Medicine and Cardiology, Chief Scientific Officer, Associate VP, Vice Dean
- 2015-2016: Interim CEO, Associated Regional University Pathologists (ARUP), major clinical reference lab[57][58]
- **Career at Merck:**
- 2017: Joined as Vice President, Head of Translational Medicine
- 2017-2021: Senior Vice President, Discovery Sciences and Translational Medicine
- January 2021-Present: EVP & President, Merck Research Laboratories[57][58]
- **Entrepreneurial:** Co-founded Recursion Pharmaceuticals, Hydra Biosciences, Navigen Pharmaceuticals[57]
- **Board:** Recursion Pharmaceuticals[58]
- **Professional:** Member, American Society for Clinical Investigation; Association of American Physicians[57][58]

Executive Vice President & President, Oncology and MSD International

Jannie Oosthuizen
Current Role: February 2026 - Present; Previous: President, Merck Human Health U.S.

- **Education:** Pharmacy degree, North-West University, South Africa[59]
- **Career at Merck (joined 2014):**
- 2014-2016: Various commercial roles
- 2016-2020: President, Merck Japan
- Led Human Health oncology business in Asia Pacific and Latin America
- Head of Global Marketing for Oncology
- ~February 2022-2026: President, Merck Human Health U.S.
- February 2026-Present: EVP & President, Oncology and MSD International[59][60][61]
- **P&L Responsibility:** Global oncology business, U.S. Oncology, and 75+ international markets outside the U.S.[19][59]
- **Pre-Merck:** 21 years at Eli Lilly (1993-2014) in South Africa and various global roles[59]

Executive Vice President & President, Specialty, Pharma & Infectious Diseases

Brian Foard
Effective: March 2, 2026

- **P&L Responsibility:** Cardiometabolic, respiratory, infectious diseases, immunology, and ophthalmology portfolios[19] [20]
- **Pre-Merck:** Previously with Sanofi (specific roles not detailed in available sources)[20]
- **Note:** Limited biographical information available; appointment announced as part of February 2026 Human Health reorganization

Senior Vice President, Head of Global Clinical Development & Chief Medical Officer

Eliav Barr, M.D.
Role confirmed as of 2025

- Leads global clinical development across Merck's therapeutic areas[62]
- Previously held various roles in clinical development and vaccine research
- Detailed career history not available in search results

Other Key Executives

Search results confirm additional executive team members exist but do not provide detailed biographies for: - Chief Digital Officer - Chief Legal Officer - Chief Human Resources Officer - Regional presidents for key markets

LinkedIn Profile URLs

Available public sources do not provide direct LinkedIn URLs for executives. Corporate profiles are available on Merck's official leadership page: https://www.merck.com/company-overview/leadership/executive-team/

---

4. Drug Portfolio

Merck's pharmaceutical portfolio generated **$58.1 billion** in sales for full-year 2025, with Animal Health adding another **$6.4 billion**.[23] The portfolio is heavily concentrated in oncology (driven by Keytruda), vaccines (Gardasil, Capvaxive), and emerging franchises in cardiometabolic and respiratory diseases.

Portfolio Summary Tables

Table 4.1: Oncology Portfolio (2025)

Product	Revenue (2025)	Growth (YoY)	Patent/Exclusivity Status	Peak Sales Potential	P&L Owner
Keytruda (pembrolizumab)	$31.7B	+7%	US patent exp Dec 2028; extensions possible to 2029-2033	$35B (2028)	Jannie Oosthuizen
Keytruda QLEX (subcut formulation)	$40M (FY); $35M Q4	Launch 2025	New 20-year exclusivity potential	Part of Keytruda family	Jannie Oosthuizen
Lenvima (lenvatinib) - alliance revenue	$1.05B	+4%	LOE 2026	~$3B (partner	Jannie Oosthuizen

Product	Revenue (2025)	Growth (YoY)	Patent/Exclusivity Status	Peak Sales Potential	P&L Owner
				Eisai)	
Lynparza (olaparib) - alliance revenue	Not specified	N/A	US LOE 2027	N/A	Jannie Oosthuizen
Welireg (belzutifan)	$509M	+37% (Q4)	Approved 2021; orphan exclusivity	$1-2B	Jannie Oosthuizen

Notes: Lenvima and Lynparza are co-developed with Eisai and AstraZeneca respectively; Merck books alliance revenue (profit share) rather than product sales.[13][14][63][64][65][66][67]

Table 4.2: Vaccines, Cardiometabolic, Respiratory & Other (2025)

Product	Revenue (2025)	Growth (YoY)	Patent/Exclusivity Status	Peak Sales Potential	P&L Owner
Gardasil/Gardasil 9 (HPV vaccine)	$5.2B	-39%	US patents 2028-2038; EU varies	$8-11B (peak was 2023)	Brian Foard
Capvaxive (PCV21 pneumococcal)	$759M	Launch 2024	Exclusivity through 2030s	$3-4B	Brian Foard
Winrevair (sotatercept)	$1.4B	+234% vs 2024	Launched 2024; orphan exclusivity	$3B	Brian Foard
Ohtuvayre (ensifentrine)	$178M (Q4 only)	Launch Aug 2024	New exclusivity ~2035+	$4B+	Brian Foard
Januvia/Janumet (sitagliptin)	$2.86B (diabetes portfolio total)	+10% portfolio	US generic entry mid-2026	Declining	Brian Foard
Bridion (sugammadex)	$499M (Q4)	+11% (Q4)	Patent exp 2026; US LOE 2027	Declining	Brian Foard
Lagevrio (molnupiravir)	$138M (Q3)	-64% (Q3 YoY)	COVID antiviral; declining demand	<$500M	Brian Foard

Notes: Q4-only figures reflect partial-year availability post-acquisition (Ohtuvayre from Verona Pharma Oct 2025). Gardasil sales collapsed in China due to economic headwinds and anti-corruption measures.[23][24][25][35][36][68][69][70]

Detailed Product Write-Ups

Keytruda (pembrolizumab) - The Crown Jewel

Revenue & Market Position: Keytruda generated **$31.7 billion** in global sales for 2025, representing 49% of Merck's total revenue and cementing its position as the world's best-selling cancer drug.[13][14] Q4 2025 sales reached $8.4 billion, up 5% year-over-year, though this included a ~$200M U.S. purchase timing headwind and foreign exchange headwinds from the Argentine peso devaluation.[71]

Growth Drivers: - **Earlier-stage indications:** Robust uptake in adjuvant and neoadjuvant settings for NSCLC, triple-negative breast cancer (TNBC), renal cell carcinoma, cervical, endometrial, and head/neck cancers[71][72] - **Metastatic indications:** Strong demand in urothelial, gastric, and endometrial cancers[71] - **Combination therapies:** Keytruda + enfortumab vedotin (Padcev) for first-line locally advanced or metastatic urothelial cancer; Keytruda + Lenvima for renal cell carcinoma[71][72] - **Subcutaneous formulation (Keytruda QLEX):** Launched Q3 2025, contributed $35M in Q4 and $40M for full year; permanent J-code expected April 2026[71]

Approved Indications (40+ FDA approvals):[73][74] - **NSCLC:** Metastatic NSCLC with PD-L1 expression (monotherapy and combinations) - **Melanoma:** Unresectable/metastatic melanoma; adjuvant for stage IIB/IIC/III - **TNBC:** High-risk early-stage TNBC (neoadjuvant + adjuvant) - **Head & Neck:** First-line metastatic/recurrent HNSCC; neoadjuvant + adjuvant with radiotherapy - **Renal Cell Carcinoma:** Various combinations - **Urothelial Cancer:** Multiple lines of therapy - **Other:** Biliary tract, Merkel cell, cutaneous squamous cell, MSI-H/dMMR tumors, TMB-high cancers[73][74]

Patent Cliff Risk: Core U.S. compound patent expires **December 2028**, though Merck holds 53 granted patents from 129 applications, including method-of-making patents that could extend exclusivity "for years beyond 2028."[15][16] The subcutaneous formulation (Keytruda QLEX) represents a product-hopping strategy to retain patients ahead of IV biosimilar entry.[16]

Medicare IRA Impact: Keytruda will likely be subject to Medicare drug price negotiation under the Inflation Reduction Act, potentially starting in 2029 for Part B biologics (≥13 years on market).[38] Merck challenged the IRA constitutionality but the program is proceeding.[38]

Competitive Landscape: Keytruda dominates the PD-1/PD-L1 inhibitor market, but faces emerging competition from Summit Therapeutics' ivonescimab, which outperformed Keytruda in one NSCLC trial.[75] However, Keytruda's broad label, subcutaneous convenience, and established market position provide defensibility.

Gardasil/Gardasil 9 - Vaccine Franchise Under Pressure

Revenue Collapse: Gardasil sales plummeted to **$5.2 billion** in 2025, down **39% year-over-year**, primarily due to China market collapse.[35][36] China sales dropped 41% in H1 2025 and 55% in Q2 2025 alone, driven by economic uncertainty, anti-corruption measures reducing healthcare incentives, and Merck's shipment pause starting January/February 2025.[36]

Indications: FDA-approved for males and females ages 9-45 to prevent: - Cervical, vulvar, vaginal, anal, oropharyngeal, and other head/neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, 58 - Genital warts (condyloma acuminata) caused by HPV types 6, 11 - Precancerous/dysplastic lesions (CIN, VIN, VaIN, AIN)[76][77]

Patent Timeline: U.S. patents expire 2028 for core patents, with extensions to 2036-2038 for certain formulations (quadrivalent vs. Gardasil 9).[36][78] No specific China patent expiration identified.

Strategic Response: Merck withdrew its $11B 2030 global sales target and ended its 7% royalty to GSK. The company approved Gardasil for males ages 9-26 in China (January 2025), the first HPV vaccine for males in that market, potentially aiding recovery.[36][79]

Winrevair (sotatercept) - Pulmonary Arterial Hypertension Blockbuster

Revenue: $1.4 billion in 2025 sales (up from $419M in partial-2024 launch year), with Q4 reaching $467M driven by >1,500 new U.S. patients and >27,000 prescriptions dispensed.[80][81]

Indication: First-in-class activin signaling inhibitor for adults with pulmonary arterial hypertension (WHO Group 1) to increase exercise ability, improve WHO Functional Class, and reduce clinical worsening events.[80]

Clinical Data: - **HYPERION Trial:** 76% reduction in clinical worsening events vs. placebo in recently diagnosed PAH patients[82] - **ZENITH Trial:** Met primary endpoint for morbidity/mortality reduction; led to FDA approval expansion in

October 2025[82] - **EU Approval:** CHMP recommended expanded indication for WHO Functional Classes II, III, and IV in December 2025[82]

Peak Sales Potential: Analysts project **$3 billion** long-term, supported by significant undiagnosed PAH population and favorable Leerink Partners survey showing only 10% of eligible patients currently on therapy.[80][83]

Acquisition: Acquired via $11.5 billion Acceleron Pharma purchase in 2021.[47]

Capvaxive (PCV21) - Adult Pneumococcal Vaccine

Revenue: $759 million in 2025 (Q1: $107M, Q2: $129M, Q3: $244M, Q4: $279M), reflecting strong U.S. launch momentum following Q3 2024 approval.[84][85]

Market Position: Direct competitor to Pfizer's Prevnar 20, with broader serotype coverage (21 vs. 20 valent) targeting the **$8.8-9.23 billion pneumococcal vaccine market** in 2025.[84][86]

Strategy: Filed exclusively for adults (not pediatric) to capture 6.7% CAGR growth in adult segment through 2031, with potential pediatric expansion via ongoing Stride-13 trial for high-risk children.[84]

Peak Potential: $3-4 billion based on market share gains and expanding adult vaccination rates.

Ohtuvayre (ensifentrine) - First-in-Class COPD Therapy

Revenue: $178 million in Q4 2025 (partial quarter post-October 7 acquisition), exceeding expectations with strong new patient starts and physician adoption.[87]

Indication: First novel inhaled mechanism for COPD maintenance treatment in over 20 years; FDA approved August 2024.[26][48]

Acquisition Rationale: Merck paid **$10 billion** for Verona Pharma (closed Oct 7, 2025) to add this asset, the company's largest acquisition since Prometheus ($10.8B).[26][48]

Peak Sales: Analysts project **over $4 billion** annually at peak penetration.[88]

Seasonality: Merck noted expected early-year softness as Medicare deductibles reset.[87]

Januvia/Janumet - Diabetes Franchise Facing Generics

Revenue: Diabetes portfolio (primarily Januvia/Janumet) totaled **$2.862 billion** in 2025, up 10% from $2.599B in 2024, with Q4 Januvia/Janumet sales of $501M (+3% YoY).[68][69]

Patent Cliff: U.S. generic entry expected **mid-2026** via patent settlements, threatening a significant portion of the $2.9B franchise.[37][89]

Growth Paradox: Despite looming generics, sales grew due to higher U.S. net pricing, offsetting lower demand in China and international markets from existing generic competition.[68][69]

Other Notable Products

- **Bridion (sugammadex):** $499M Q4 2025 (+11% YoY); neuromuscular blockade reversal agent; patent expiration 2026, U.S. LOE 2027[37][68]
- **Welireg (belzutifan):** $509M FY 2025 ($220M Q4, +37% growth); HIF-2α inhibitor for renal cell carcinoma and von Hippel-Lindau disease[90][91]
- **Lenvima (lenvatinib):** Alliance revenue $1.05B (+4%); co-developed with Eisai for RCC and other cancers; LOE 2026[63][64]
- **Lagevrio (molnupiravir):** $138M Q3 2025 (-64% YoY); COVID-19 antiviral with declining pandemic demand[70]

5. Top 5 CEO Focus Drugs

Based on Q4 2025 earnings call commentary, investor presentations, and strategic priorities outlined by CEO Rob Davis, the following drugs represent Merck's primary growth focus:[21][92][93]

1. Keytruda (pembrolizumab) - Maximizing Pre-LOE Value

CEO Priority: Extend Keytruda dominance through label expansions, combination approvals, and subcutaneous formulation adoption to maximize revenue before 2028 patent expiration.

Revenue & Growth: $31.7B (2025), +7% YoY; Q4 $8.4B (+5% despite headwinds)[13][14]

Strategic Initiatives: - **Keytruda QLEX (subcutaneous):** Launched Q3 2025; aim to shift 40% of patients by 2027 ahead of IV biosimilar entry[16][71] - **Earlier-stage expansions:** Adjuvant/neoadjuvant indications in breast, lung, bladder, kidney cancers to broaden patient pool - **Combination strategies:** Padcev partnership for bladder cancer; Lenvima for RCC; potential Daiichi Sankyo ADC combinations

Competitive Positioning: Dominant market leader with 40+ FDA approvals; faces emerging competition from bispecific antibodies (ivonescimab) but maintains first-mover advantage and physician familiarity.

2028 Outlook: Analysts project $33.7B sales in 2028 before patent cliff drives decline to $27.4B in 2029, absent successful patent extensions or Medicare IRA pricing impact.[15]

2. Winrevair (sotatercept) - Post-Keytruda Anchor

CEO Priority: Establish Winrevair as the standard of care in PAH and drive global adoption to create a multi-billion-dollar franchise offsetting Keytruda erosion.

Revenue & Growth: $1.4B (2025), +234% vs. 2024; Q4 $467M with >27,000 prescriptions[80][81]

Strategic Rationale: - First-in-class mechanism targeting activin signaling pathway - Orphan drug exclusivity in rare disease (PAH prevalence ~15-50 per million adults)[94] - Strong Phase 3 data: 76% reduction in clinical worsening (HYPERION); mortality/morbidity benefit (ZENITH)[82] - Significant white space: Leerink survey shows only 10% of eligible patients currently treated[83]

Peak Sales Potential: $3B+, supported by expanding label (WHO FC II-IV) and international approvals

Competitive Moat: No direct mechanism competitors; competes with Opsumit, Uptravi, Opsynvi (different MOAs)

3. Ohtuvayre (ensifentrine) - COPD Market Disruptor

CEO Priority: Rapidly scale Ohtuvayre as the first novel COPD maintenance therapy in 20+ years, targeting a massive underserved population.

Revenue & Growth: $178M Q4 2025 (partial quarter post-acquisition); strong new patient starts exceeding expectations[87]

Market Opportunity: - COPD prevalence: 65-81% of spirometrically-confirmed cases **undiagnosed**[95] - U.S.: 18+ million with impaired lung function; only 8.5M diagnosed[95] - Global: Widespread underdiagnosis, especially in primary care settings[95]

Acquisition Justification: $10B Verona Pharma deal closed Oct 2025; ensifentrine launched Aug 2024 with rapid uptake[26][48]

Peak Sales Potential: $4B+ at full penetration; dual bronchodilator and anti-inflammatory mechanism differentiates from existing therapies

2026 Challenge: Medicare deductible reset seasonality may temper Q1 2026 growth[87]

4. Gardasil 9 - Stabilization and Recovery

CEO Priority: Stabilize Gardasil franchise after 2025 China collapse; expand into underserved markets and male vaccination to restore growth trajectory.

Revenue & Challenges: $5.2B (2025), -39% YoY; China sales down 55% in Q2 2025[35][36]

Recovery Strategy: - **China male indication:** Approved Jan 2025 for males 9-26, first HPV vaccine for males in China[79] - **Pricing/demand normalization:** Post-COVID/anti-corruption headwinds expected to ease - **Global expansion:** Continue rollout in emerging markets with low vaccination rates

Patent Defense: U.S. patents 2028-2038; seek label extensions and lifecycle management to delay biosimilar/generic entry[36][78]

Realistic Outlook: Unlikely to return to $8.6B (2024) peak; stabilization at $6-7B range by 2027-2028 considered success

5. Capvaxive (PCV21) - Vaccine Portfolio Diversification

CEO Priority: Capture adult pneumococcal market share from Pfizer's Prevnar 20 to offset Gardasil headwinds and build sustainable vaccine franchise.

Revenue & Growth: $759M (2025), strong quarterly progression (Q1 $107M → Q4 $279M)[84][85]

Market Dynamics: - $8.8-9.23B global pneumococcal vaccine market (2025)[84][86] - North America represents 38.53% of market; U.S. adult segment growing at 6.7% CAGR through 2031[84] - Merck's 21-valent coverage vs. Pfizer's 20-valent offers marginal clinical differentiation

Strategic Position: Adult-only launch avoids pediatric competition; focuses on higher-margin, less price-sensitive segment

Peak Potential: $3-4B if Merck captures 30-40% adult market share; pediatric expansion via Stride-13 trial could add upside

---

6. P&L Owners

Merck reorganized its Human Health business in **February 2026** into two units with dedicated P&L accountability:[19][20]

Oncology Business Unit

P&L Owner: Jannie Oosthuizen
Title: Executive Vice President and President, Oncology and MSD International
Appointed: February 2026 (restructuring); previously President, Merck Human Health U.S. (~Feb 2022-2026)

Scope of Responsibility: - **Global Oncology:** Full P&L for Keytruda, Lenvima (alliance), Welireg, and oncology pipeline - **U.S. Oncology:** Direct P&L for U.S. oncology commercial operations - **MSD International:** P&L for 75+ markets outside the United States (full Human Health portfolio, not oncology-only)[59][96]

Background: - Pharmacy degree, North-West University (South Africa) - 21 years at Eli Lilly (1993-2014): South Africa and global commercial roles - Joined Merck 2014: Various commercial roles → President, Japan (2016-2020) → Led Asia Pacific/Latin America oncology → Head of Global Marketing, Oncology → President, Human Health U.S. (2022) → Current role (2026)[59][96]

LinkedIn: Not publicly available in search results
Verification: Confirmed via Merck official personnel page and press releases[19][59][96]

Specialty, Pharma & Infectious Diseases Business Unit

P&L Owner: Brian Foard
Title: Executive Vice President and President, Specialty, Pharma & Infectious Diseases
Appointed: March 2, 2026 (effective date)

Scope of Responsibility: - **Cardiometabolic/Respiratory:** Winrevair, Ohtuvayre, diabetes franchise (Januvia/Janumet) - **Infectious Diseases:** Lagevrio, CD388 (Cidara acquisition), HIV pipeline - **Immunology:** MK-7240 (Prometheus acquisition) for IBD - **Ophthalmology:** Restoret (EyeBio acquisition) for wet AMD - **Vaccines:** Gardasil, Capvaxive, pneumococcal portfolio[19][20]

Background: - Previously with Sanofi (specific roles not detailed in available sources) - Appointed as part of Human Health reorganization to lead non-oncology franchises[20]

LinkedIn: Not publicly available
Verification: Confirmed via Merck press releases and personnel announcements[19][20]

Merck Research Laboratories

P&L Owner: Dean Y. Li, M.D., Ph.D.
Title: Executive Vice President and President, Merck Research Laboratories
Appointed: January 2021

Scope: Not traditional product P&L; responsible for R&D budget (~$15.8B in 2025, 24% of revenue) and pipeline execution[10][57]

LinkedIn: Not provided in search results
Verification: Confirmed via Merck leadership page[57]

Regional / Country P&L Owners

Search results identify **country-level leadership** (e.g., Matthew Thornhill for Vaccines in Merck Canada; André Galarneau for Oncology in Merck Canada)[97], but these are not global P&L roles.

Global therapeutic franchise leads below EVP level (e.g., Head of Diabetes, Head of Vaccines) are **not publicly confirmed** in available sources. Merck's official leadership page lists only EVP-level executives.[98]

Data Gaps

- **LinkedIn URLs:** Not available in public search results for any executives
- **Therapeutic franchise leads:** Below-EVP P&L owners (e.g., Global Head of Diabetes, Global Head of Vaccines) are not publicly disclosed
- **Animal Health P&L:** Animal Health business unit leadership not specified in available sources (separate from Human Health reorganization)

Explicit Statement: For franchise leads below EVP level (e.g., specific diabetes or vaccine global commercial heads), **data is not publicly confirmed**. Merck does not publicly disclose organizational charts beyond the executive team level.

---

7. R&D Pipeline

Merck maintains one of pharma's most aggressive R&D programs, investing **$15.8 billion (24% of revenue)** in 2025.[10] The company has nearly tripled its Phase 3 portfolio since 2021 through strategic M&A and internal development, targeting **over $70 billion in non-risk-adjusted commercial opportunities** by the mid-2030s.[17][18]

Key Phase 3 Programs (2026+ Readouts Expected)

Asset	Indication	Phase	Partner/Source	Expected Milestone	Notes
Islatravir (MK-8591)	HIV PrEP	Phase 3	In-house	Phase 3 data late 2025; filing 2026	Novel NRTTI; long-acting oral; resumed at lower doses post-2021 safety pause[99][100]
MK-7240 (PRA023)	Inflammatory Bowel Disease (UC/Crohn's)	Phase 3	Prometheus ($10.8B)	Filing ~2026	Anti-TL1A mAb; potential first-line IBD therapy[27][28][99]
MK-2870	Solid tumors (TROP2+)	Phase 3	Kelun partnership	Data 2025-26	TROP2-directed ADC; competes with Dato-DXd, Trodelvy[99]
Zilovertamab vedotin	Hematologic cancers	Phase 3	VelosBio acquisition	Potential launch 2026-27	ROR1-targeted ADC[99]
Patritumab deruxtecan (HER3-DXd)	NSCLC, breast cancer	Phase 3	Daiichi Sankyo ($22B)	Multiple readouts 2026+	Withdrew US filing for lung cancer; active trials ongoing[33][101]
Ifinatamab deruxtecan (I-DXd)	Small cell lung cancer, others	Phase 3	Daiichi Sankyo ($22B)	Breakthrough designation SCLC	Partial hold on IDeate-Lung02 resolved; other studies continue[33][102]
Raludotatug deruxtecan (R-DXd)	Solid tumors	Phase 3	Daiichi Sankyo ($22B)	TBD	Third ADC in Daiichi collaboration[33]
CD388	Influenza prevention	Phase 3	Cidara ($9.2B)	Regulatory path TBD	Long-acting, strain-agnostic antiviral; completed Phase 2b NAVIGATE[29][30][103]
Restoret (EYE103)	Wet AMD, DME	Phase 3	EyeBio ($3B)	BRUNELLO trial completion Sept 2026 (accelerated)	Trispecific antibody for retinal vascular leakage[31][32][104]

Asset	Indication	Phase	Partner/Source	Expected Milestone	Notes
Subcutaneous pembrolizumab	Multiple cancers	Post-approval expansion	In-house	Ongoing label expansions	Keytruda QLEX approved 2025; expanding to all Keytruda indications[71]
Welireg + Lenvima	Advanced RCC	Phase 3	In-house + Eisai	Met PFS endpoint Oct 2025	First regimen superior to cabozantinib in post-treatment RCC[64][105]

Early-Stage Pipeline Highlights

Oncology: - MK-6070 (DLL3-targeting T-cell engager) in partnership with Daiichi Sankyo for small cell lung cancer[106] - Calderasib (KRAS G12C inhibitor) in Phase 2 for NSCLC - Multiple Keytruda combinations in Phase 2/3 across tumor types

Vaccines: - V116 (pneumococcal conjugate vaccine) - competing with Capvaxive in development - mRNA-4157 (personalized cancer vaccine) in partnership with Moderna for melanoma and other cancers - Clesrovimab (RSV monoclonal antibody) - no confirmed Phase 3 timeline in search results[100]

Immunology: - MK-7240 derivatives and follow-on IBD programs post-Prometheus acquisition

Cardiometabolic: - Winrevair label expansions (pulmonary hypertension subtypes beyond WHO Group 1)

Strategic Pipeline Approach

Merck's pipeline strategy emphasizes: 1. **"Swinging for the fences":** High-bar endpoints like overall survival rather than incremental PFS gains[99] 2. **Ruthless prioritization:** Terminated underperforming programs (e.g., TIGIT, LAG-3 combinations) to focus capital[99] 3. **M&A-driven diversification:** $50B+ in acquisitions since 2021 to fill post-Keytruda gap[26][27][29][31][33] 4. **Lifecycle management:** Keytruda QLEX, combination approvals to extend market exclusivity[16][71]

Pipeline Execution Risks

- **High failure rates:** Phase 3 success rates industry-wide ~50-60%; Merck's aggressive bet sizing creates binary outcomes
- **Integration challenges:** Multiple simultaneous acquisitions strain R&D organization
- **Regulatory uncertainty:** IRA pricing, accelerated approval confirmations (e.g., Keytruda head/neck indication)
- **Competition:** Me-too assets in ADCs, PD-1 combinations face crowded markets

---

8. Top Geographies

Merck derives approximately **50% of revenue from the United States**, with the remainder distributed across Europe, Asia Pacific, Latin America, and other regions.[107]

Geographic Revenue Breakdown (2025)

Region	Revenue (USD)	% of Total	Growth YoY	Notes
United States	~$32.5B (estimated)	~50%	N/A	Derived from 50% proportion cited for 2024-2025[107]
China	~$5.0B (estimated/declining)	~7-8%	-41% (H1 2025)	Gardasil collapse drove sharp decline from $5.49B (2024)[107][108]
Europe	Not specified	N/A	+12.16% (recent period)	Europe, Middle East, Africa combined growth[107]
Japan	Included in Asia Pacific	N/A	Decline (Gardasil)	Specific 2025 figure not available[107]
Asia Pacific (ex-China/Japan)	~$3.06B (2024 baseline)	~4-5%	N/A	Historical reference only[109]
Latin America	~$3.46B (2024 baseline)	~5%	N/A	Historical reference only[109]
Other Regions	~$2.56B (2024 baseline)	~4%	N/A	Historical reference only[109]
TOTAL WORLDWIDE	**$65.0B**	**100%**	+1% nominal; +2% ex-FX	Full-year 2025 actual[5][6]

Data Gaps and Estimation Notes:

- **U.S. Revenue:** No exact 2025 figure provided in search results; estimated at 50% of total based on historical patterns and sources indicating "approximately half" from U.S.[107]
- **China:** 2024 revenue was $5.49B; 2025 experienced sharp decline due to Gardasil collapse (41% H1 drop, 55% Q2 drop)[107][108]
- **Regional Detail:** Merck does not publicly disclose detailed geographic splits beyond U.S./Ex-U.S. in quarterly reports; most granular data comes from full-year 10-K filings (not yet available for 2025 as of March 2026)
- **FX Impact:** 2025 growth was +2% excluding foreign exchange effects vs. +1% nominal, indicating modest FX headwinds[5][6]

Geographic Strategic Notes

United States - Core Market: - Keytruda dominance (~60% of product's global sales from U.S. historically)[107] - Premium pricing environment despite IRA negotiation pressures - Strong new product uptake (Winrevair, Capvaxive, Ohtuvayre)

China - Major Risk Factor: - Gardasil sales collapsed from $3.5B (2024 in China) to minimal levels in 2025[36][108] - Economic uncertainty, anti-corruption crackdown, and shipment pauses drove decline - Male HPV vaccine approval (Jan 2025) provides recovery opportunity[79] - Long-term growth potential remains if macro environment stabilizes

Europe - Stable Growth: - Double-digit growth (12.16%) in Europe/Middle East/Africa combined[107] - Keytruda, Gardasil, and new launches driving expansion - Regulatory environment generally favorable; EU Keytruda patents extend to 2031[110]

Japan - Mature Market: - Gardasil headwinds impacted 2025 performance[107] - Strong Keytruda adoption; Welireg approval June 2025[111] - Aging population creates opportunities for oncology, vaccines

Emerging Markets: - Latin America, Asia Pacific (ex-China/Japan) represent ~8-10% of revenue - Growth potential in underserved populations for vaccines, oncology - Pricing pressure and generic competition limit margin expansion

---

9. Competitive Landscape

Merck competes across multiple therapeutic areas with varying intensity and market positioning.

Oncology - PD-1/PD-L1 Inhibitors

Merck's Position: Dominant market leader with Keytruda ($31.7B, 2025)

Key Competitors:

Company	Product	Mechanism	2024-2025 Sales (Est.)	Competitive Positioning
Bristol Myers Squibb	Opdivo (nivolumab)	PD-1 inhibitor	~$8-9B	First-to-market PD-1; lost label race to Keytruda in multiple indications; growing but Revlimid LOE limits R&D investment[112]
Roche	Tecentriq (atezolizumab)	PD-L1 inhibitor	~$3-4B	Combination strategies with chemo; smaller share vs. Keytruda/Opdivo
AstraZeneca	Imfinzi (durvalumab)	PD-L1 inhibitor	~$3B	Stage III NSCLC maintenance niche; limited head-to-head success vs. Keytruda
Summit Therapeutics	Ivonescimab	Bispecific (PD-1/VEGF)	In development	**Emerging threat:** Outperformed Keytruda in one NSCLC trial; Chinese-developed bispecific[75]

Merck's Competitive Advantages: - Broadest FDA label (40+ approvals across tumor types, lines of therapy, combinations)[73] - First-mover advantage in many indications (e.g., first-line NSCLC) - Subcutaneous formulation (Keytruda QLEX) offers convenience edge[71] - Physician familiarity and treatment algorithms centered on Keytruda

Threats: - 2028 patent expiration opens door to biosimilars - Bispecific antibodies (ivonescimab, others) may offer efficacy advantages - CAR-T, ADCs, and other modalities shifting treatment paradigms in some cancers

Vaccines - HPV and Pneumococcal

HPV Vaccines:

Company	Product	Valency	Market Position
Merck	Gardasil 9	9-valent	Dominant global share (~$5.2B, 2025); China collapse major risk[35]
GSK	Cervarix	Bivalent	Minimal share; mostly withdrawn from markets

Merck holds near-monopoly in HPV vaccines; key competition is from national immunization programs' budget constraints rather than direct product competition.

Pneumococcal Vaccines (Adult):

Company	Product	Valency	2025 Position
Merck	Capvaxive	21-valent	$759M; rapidly gaining share post-2024 launch[84]

Company	Product	Valency	2025 Position
Pfizer	Prevnar 20	20-valent	Incumbent leader; ~$6B+ total pneumococcal (adult + pediatric)

Adult pneumococcal market ($8.8B+ globally) seeing intensifying competition; Merck's one extra serotype offers marginal differentiation. Market share battle will depend on real-world efficacy data, provider preference, and contracting.

Pulmonary Arterial Hypertension

Merck's Position: Winrevair ($1.4B, 2025) - first-in-class activin signaling inhibitor[80]

Competitors:

Company	Product	Mechanism	Sales (Est.)
Johnson & Johnson	Uptravi (selexipag)	Prostacyclin receptor agonist	~$2B
Janssen	Opsumit (macitentan)	Endothelin receptor antagonist	~$2B (2023)
Janssen	Opsynvi (macitentan + tadalafil)	Dual endothelin/PDE5 inhibitor	Launched 2023

Winrevair's differentiated mechanism creates complementary positioning rather than head-to-head substitution; most PAH patients receive combination therapy. Merck aims to establish Winrevair as backbone therapy added to existing regimens.

COPD - Maintenance Therapies

Merck's Position: Ohtuvayre ($178M Q4 2025) - first-in-class dual inhibitor (PDE3/PDE4)[87]

Established Competitors:

Company	Product	Mechanism	Market Position
GSK	Trelegy Ellipta	Triple therapy (ICS/LAMA/LABA)	>$3B; market leader
AstraZeneca	Breztri Aerosphere	Triple therapy (ICS/LAMA/LABA)	~$1-2B
Boehringer Ingelheim	Spiriva (tiotropium)	LAMA	~$3B (declining); generic entry

Ohtuvayre differentiates via novel mechanism and potential for patients intolerant of steroids (ICS). Key challenge: overcoming physician inertia in COPD where triple therapy is entrenched.

Diabetes - DPP-4 Inhibitors

Merck's Position: Januvia/Janumet ($2.86B, 2025) - facing mid-2026 generic entry[68][69][89]

Competitive Landscape: DPP-4 class largely commoditized; competition from: - **GLP-1 agonists:** Novo Nordisk's Ozempic/Wegovy, Lilly's Mounjaro/Zepbound dominating diabetes/obesity (~$20B+ combined) - **SGLT2 inhibitors:** Jardiance (Lilly/Boehringer), Farxiga (AstraZeneca) - **Generic DPP-4s:** Sitagliptin generics mid-2026; other DPP-4s already generic

Merck's diabetes franchise in managed decline; company not investing in next-gen diabetes R&D.

Overall Market Share and Positioning

Oncology Dominance: Merck's Keytruda market leadership provides premium valuation (P/E ~16.2x, below pharma average but justified by patent cliff risk)[113]

Vaccines Strength: Gardasil's China issues aside, Merck remains vaccine powerhouse; Capvaxive launch success reinforces franchise

Emerging Franchises: Winrevair, Ohtuvayre, Welireg building credibility as post-Keytruda growth drivers, but collective revenue (~$2-3B) still dwarfed by Keytruda ($32B)

Pipeline Quality: $70B+ opportunity set via M&A creates optionality, but execution risk high given multiple simultaneous integrations[17][18]

---

10. Risks and Challenges

1. Keytruda Patent Cliff (Critical Risk)

Timeline: December 2028 primary U.S. compound patent expiration[15][16]

Revenue Impact: - Keytruda represents 49% of 2025 total revenue ($31.7B of $65B)[13][14] - Analysts project sales decline from $33.7B (2028) to $27.4B (2029) post-LOE[15] - Even with patent extensions and Keytruda QLEX lifecycle management, significant biosimilar erosion likely by 2030

Mitigation Strategies: - **Subcutaneous formulation (Keytruda QLEX):** Launched 2025; aiming for 40% patient shift by 2027[16][71] - **Patent thicket:** 53 granted patents from 129 applications; method-of-making patents could extend exclusivity "for years"[16] - **Label expansions:** Broader indications increase switching costs for biosimilars - **Pipeline diversification:** $70B+ opportunity set to fill revenue gap[17][18]

Residual Risk: No amount of pipeline building fully replaces a $32B anchor product; investor confidence depends on execution of multiple launches simultaneously.

2. Gardasil China Collapse and Patent Expiration

2025 Revenue Collapse: Sales plunged 39% to $5.2B, driven by 55% Q2 decline in China[35][36]

Root Causes: - Economic uncertainty in China reducing consumer spending on elective vaccines - Anti-corruption crackdown limiting healthcare provider incentives - Merck shipment pauses (Jan/Feb 2025) to manage inventory[36]

Patent Timeline: U.S. patents expire 2028-2038 depending on formulation[36][78]

Recovery Uncertainty: - Male vaccination approval (Jan 2025) in China provides new growth vector[79] - Macro environment must stabilize for demand recovery - Patent cliff compounds revenue pressure even if demand recovers

Mitigant: Gardasil represented only 8% of 2025 revenue ($5.2B of $65B); less critical than Keytruda but still material

3. Multiple Patent Cliffs (2026-2028)

Product	2025 Revenue	LOE Timeline	Risk Level
Januvia/Janumet	$2.86B (diabetes total)	Mid-2026 generic entry	**High** - immediate threat[68][89]
Bridion	~$2B (annualized from Q4)	Patent exp 2026; US LOE 2027	**Medium** - smaller franchise[37][68]

Product	2025 Revenue	LOE Timeline	Risk Level
Lenvima (alliance)	$1.05B (alliance revenue)	LOE 2026	**Medium** - Eisai bears primary impact[63]
Lynparza (alliance)	N/A	US LOE 2027	**Low** - alliance revenue model[114]
Keytruda	$31.7B	December 2028	**Critical** - see above[13][15]
Gardasil 9	$5.2B	2028-2038	**High** - compounded by China issues[35][36]

Combined Impact: Products representing ~$40B+ in revenue face LOE within 4 years, creating a "perfect storm" requiring flawless new product execution.

4. Inflation Reduction Act (IRA) Medicare Drug Pricing

Mechanism: IRA allows Medicare to negotiate prices for high-spend drugs: - Part D (retail) drugs: ≥9 years on market eligible starting 2026 negotiations - Part B (physician-administered) biologics: ≥13 years eligible starting 2028 negotiations[38]

Keytruda Exposure: - Approved 2014; reaches 13-year threshold in 2027 - Likely subject to 2029 negotiation (for 2030 pricing) as top Medicare Part B spend - Potential 25-60% price reduction depending on manufacturer's "maximum fair price" calculation[38]

Merck's Response: - Filed constitutional challenge (Fifth and First Amendment violations); lawsuit dismissed, program proceeding[38] - Public advocacy against IRA's "negative impact on patient-focused innovation"[115] - Financial modeling assumes Keytruda price cuts post-2029

Broader Portfolio Impact: Gardasil, Januvia, other high-revenue products may face subsequent negotiation rounds

Investor Concern: IRA adds downside to already-challenged Keytruda post-2028 outlook; further compresses revenue expectations

5. Pipeline Execution Risk

M&A Integration Challenges: - **$50B+ in acquisitions (2021-2026):** Verona ($10B), Prometheus ($10.8B), Cidara ($9.2B), Acceleron ($11.5B), EyeBio ($3B), Daiichi collaboration ($22B)[26][27][29][31][33][47] - **Simultaneous integration:** R&D organization absorbing multiple programs across oncology, respiratory, immunology, antivirals, ophthalmology - **Execution risk:** Phase 3 failures, regulatory delays, or commercial disappointments amplified by binary bet sizing

Recent Setbacks: - Patritumab deruxtecan: Withdrew US filing for lung cancer after trial miss[101] - Ifinatamab deruxtecan: Partial FDA hold on Phase 3 (later resolved)[102]

High-Stakes Dependencies: - MK-7240 (IBD): Must succeed to justify $10.8B Prometheus price[27][28] - CD388 (influenza): $9.2B Cidara bet on unproven prevention market[29][30] - Daiichi ADCs: $22B upfront + milestones require multiple approvals[33]

Mitigation: Merck's "swing for the fences" strategy accepts high failure rates but concentrates risk

6. Foreign Exchange Exposure

2025 Impact: Revenue growth +1% nominal vs. +2% ex-FX, indicating ~100bps FX headwind[5][6]

Key Exposures: - **Argentine peso:** Cited as Q4 2025 headwind for Keytruda sales[71] - **Chinese yuan:** Gardasil decline compounded by currency weakness - **Euro, Yen:** European and Japanese markets represent significant revenue base

Hedging: Merck employs FX hedging, but ~50% ex-U.S. revenue creates structural exposure

7. Competitive Threats

Emerging Oncology Modalities: - **Bispecific antibodies:** Ivonescimab (Summit) outperformed Keytruda in NSCLC trial; threatens Keytruda dominance[75] - **ADCs:** Daiichi, Seagen, AstraZeneca, others advancing antibody-drug conjugates with superior efficacy in some settings - **CAR-T:** Cell therapies displacing chemotherapy + immunotherapy in hematologic cancers

COPD Incumbents: GSK's Trelegy ($3B+), AstraZeneca's Breztri entrenched; Ohtuvayre must displace established algorithms

Vaccine Competition: Pfizer's pneumococcal franchise, potential new HPV entrants (Chinese manufacturers)

8. Regulatory and Pricing Pressure

Global Trends: - **Europe:** Reference pricing, HTA requirements, and cost-effectiveness thresholds limit pricing power - **China:** National drug price negotiations (NRDL) demanding steep discounts; volume-based procurement (VBP) - **U.S. IRA:** See #4 above

Impact: Margin compression even for successful new products; Keytruda-level profitability unlikely to repeat

9. R&D Productivity

Investment Level: $15.8B (24% of revenue) in 2025 - among industry's highest R&D intensity[10]

ROI Concerns: - Heavy M&A reliance vs. internal discovery suggests internal R&D productivity challenges - $50B+ in acquisitions required to fill Keytruda gap = expensive innovation model - Industry-wide Phase 3 failure rates (~40-50%) apply to Merck's expanded pipeline

Mitigation: Merck's clinical development expertise (Dean Li leadership) and rigorous portfolio prioritization (terminating underperformers)[99]

---

11. Outlook and Valuation Context

Medium-Term Financial Targets

2026 Guidance (Official): - **Revenue:** $65.5-67.0 billion (+1-3% growth vs. 2025)[21][22] - **Non-GAAP EPS:** $5.00-5.15 (midpoint $5.08)[21][22] - **Key Drivers:** Oncology strength (Keytruda + Welireg), new launches (Winrevair, Ohtuvayre, Capvaxive), Animal Health growth - **Headwinds:** $2.5B headwind from Gardasil, generic competition, FX[21]

2027-2028 Outlook (Analyst Estimates): - **2027 EPS:** ~$9.78 (analyst consensus)[116] - **2028 EPS:** ~$10.82; EBIT ~$33.6B[116] - **Revenue trajectory:** Modest growth to ~$70B by 2028 before Keytruda LOE impact[116]

Post-2028 "Keytruda Cliff" Scenario: - **2029 Revenue:** Potential decline to $60-65B range if Keytruda falls to $27B (from $34B 2028 peak)[15] - **Recovery path:** Dependent on pipeline execution (Winrevair, Ohtuvayre, MK-7240, Daiichi ADCs, etc.) - **$70B Pipeline Opportunity:** Management targets $70B+ in non-risk-adjusted sales by mid-2030s from current pipeline, implying return to growth by 2031-2033[17][18]

Valuation Metrics (March 2026)

Market Data: | Metric | Value | Industry Comparison | |--------|-------|---------------------| | **Market Cap** | $289-302B | 4th largest pharma (behind Lilly, Novo, J&J) | | **Enterprise Value** | $342B | Reflects net debt position | | **Stock Price** | $119-122 | YTD 2026: +10-15% | | **P/E Ratio (TTM)** | 16.2x | Below pharma average (19.9x); peer average 25.9x[113] | | **EV/EBITDA** | ~11-12x (estimated) | Industry median ~13-15x | | **Dividend Yield** | ~2.5% (estimated) | Competitive with large-cap pharma |

Valuation Analysis:

Bear Case (Current Market Reflects): - P/E discount (16.2x vs. peers' 25.9x) prices in Keytruda cliff risk[113] - Limited multiple expansion until pipeline de-risks - Fair value ~$110-120 (current range)

Base Case (Analyst Median): - Successful pipeline execution delivers $70B mid-2030s revenue - Keytruda erosion offset by 2030-2032 as new products ramp - DCF intrinsic value ~$210/share (assumes 5.25% long-term revenue growth)[113] - Target price: $127-159 (varies by analyst)[116][117]

Bull Case: - Keytruda patent extensions to 2031-2033 via method-of-making IP[15][16] - Pipeline overdelivers: MK-7240 becomes $5B+ IBD blockbuster; Ohtuvayre reaches $6B+; Daiichi ADCs yield multiple approvals - IRA impact less severe than feared - Target price: $180-210

Key Valuation Drivers: 1. **2026-2028 new product uptake** (Winrevair, Ohtuvayre, Capvaxive) 2. **Keytruda QLEX adoption** (40% conversion by 2027 target) 3. **Pipeline Phase 3 readouts** (MK-7240, islatravir, Daiichi ADCs) 4. **China recovery** for Gardasil (stabilization vs. further decline)

Peer Comparison

Company	Market Cap	2025 Revenue	P/E Ratio	Key Franchise	Patent Cliff Risk
Eli Lilly (LLY)	~$800B	~$45B	40-50x	GLP-1 (Mounjaro/Zepbound)	Low near-term
Novo Nordisk (NVO)	~$500B	~$35B	30-35x	GLP-1 (Ozempic/Wegovy)	Low near-term
Johnson & Johnson (JNJ)	~$400B	~$85B (diversified)	15-18x	Diversified (devices, consumer)	Moderate
Merck (MRK)	~$290B	$65B	16.2x	Keytruda (oncology)	**High (2028)**
AbbVie (ABBV)	~$280B	~$55B	14-16x	Humira (post-LOE), Skyrizi/Rinvoq	Humira already LOE
Bristol Myers (BMY)	~$120B	~$45B	8-12x	Opdivo, Eliquis	High (Eliquis 2026-2028)

Positioning: Merck trades at a discount to quality pharma (Lilly, Novo) due to patent cliff, but premium to BMY reflecting stronger pipeline and Keytruda's remaining runway. Closer to JNJ, AbbVie on valuation despite less diversification.

Investment Thesis Summary

Bull Thesis: - Keytruda dominance continues through 2028; $32-35B revenue at peak - Pipeline de-risks: $70B opportunity realizes $40-50B by mid-2030s - New products (Winrevair, Ohtuvayre, Capvaxive, MK-7240) collectively deliver $15-20B by 2030 - Patent extensions push Keytruda erosion to 2030-2031 - P/E re-rates to 20-22x as pipeline visibility improves - Upside to $150-180/share

Bear Thesis: - Keytruda cliff hits hard in 2029; biosimilar erosion faster than expected - IRA pricing cuts 30-40% from 2030 Keytruda revenue - Pipeline failures: MK-7240 misses, Daiichi ADCs disappoint, Ohtuvayre slow uptake - Gardasil continues

China decline; other markets soften - Generic Januvia (2026), Bridion (2027) compress near-term earnings - P/E stays compressed at 12-15x; downside to $90-100/share

Neutral/Current Consensus: - Keytruda performs to 2028; moderate biosimilar impact 2029+ - Pipeline delivers ~50% of $70B opportunity ($35B) by mid-2030s - Revenue trough 2029-2030 at $60-62B, recovery to $68-72B by 2033 - Fair value ~$120-140/share; hold rating with modest upside

---

12. Patent/Exclusivity Summary Table

Product	Indication(s)	US Exclusivity	EU Exclusivity	Key Risk
Keytruda (IV)	Multiple cancers (40+ indications)	Dec 2028 (compound patent); extensions possible to 2029-2033 via method patents	~2031	Biosimilar entry 2029; IRA pricing 2029-2030; patent litigation uncertainty[15][16][110]
Keytruda QLEX (subcut)	Same as IV Keytruda	New 20-year exclusivity (~2045) potential via formulation patents	Similar to IV + formulation protection	Uptake dependent on physician/patient adoption; IV biosimilars may still erode market[16][71]
Gardasil 9	HPV-related cancers, genital warts	2028-2038 (varies by patent; quadrivalent 2038-12-19, 9-valent 2038-12-04)	Varies by country; China patent unclear	Biosimilar/generic entry 2029+; China market already collapsed; competitive vaccines unlikely near-term[36][78]
Januvia/Janumet	Type 2 diabetes (DPP-4 inhibitor)	**Mid-2026 generic entry via settlement**	Generic competition already in some countries	Generic entry imminent; franchise revenue decline 50-70% by 2027[37][68][89]
Bridion	Neuromuscular blockade reversal	Patent exp 2026; US LOE **2027**	Generic competition varies	Generic entry 2027-2028; international generics already present[37][68]
Winrevair	Pulmonary arterial hypertension	Orphan exclusivity + standard patents (~2031-2035 estimated)	Similar orphan/patent protection	Orphan designation provides 7-year exclusivity; limited biosimilar risk in rare disease[80]
Capvaxive	Pneumococcal disease (adults)	Standard vaccine exclusivity (~2034-2038 estimated)	Similar	Biosimilar vaccines rare; competitive threat from Pfizer Prevnar variants[84]
Ohtuvayre	COPD maintenance	New chemical entity; exclusivity through ~2035+	Similar	Generic unlikely before 2035; competitive branded COPD therapies main risk[26][87]
Welireg	RCC, VHL disease	Orphan exclusivity + patents (~2028-	Similar	Orphan protection for VHL; RCC indication more

Product	Indication(s)	US Exclusivity	EU Exclusivity	Key Risk
		2031 orphan; 2035+ patents)		vulnerable to competition[90]
Lenvima (alliance with Eisai)	Multiple cancers	**LOE 2026**	Varies	Eisai bears primary exclusivity risk; Merck alliance revenue declines 2026-2027[63]
Lynparza (alliance with AstraZeneca)	Ovarian, breast, prostate cancers	**US LOE 2027**	Varies	AstraZeneca primary; Merck alliance revenue impact moderate[114]

Patent Strategy Notes:

1. **Keytruda Lifecycle Management:** Most critical; subcutaneous formulation, combination approvals, and method-of-making patents aim to extend effective exclusivity beyond 2028[16]
2. **Orphan Drug Exclusivity:** Winrevair, Welireg (VHL indication) benefit from 7-year FDA orphan exclusivity independent of patents[80][90]
3. **Vaccine Exclusivity:** Biological complexity and manufacturing barriers create higher barriers to biosimilar entry vs. small molecules; Gardasil, Capvaxive face limited near-term competition[36][84]
4. **Early LOE Exposure:** Januvia (2026), Bridion (2027), Lenvima (2026) represent ~$5-6B in revenue facing near-term exclusivity loss before Keytruda cliff[37][63][68]
5. **Geographic Variations:** U.S. patent terms cited; EU, Japan, China exclusivity may differ by 1-3 years; China-specific data limited for most products

---

Ada Patient Finder Analysis

This section evaluates Merck's major drugs and pipeline assets for compatibility with Ada Patient Finder's patient identification and navigation platform, focusing on conditions with diagnostic delay, high per-patient revenue, and significant underdiagnosis rates.

Evaluation Criteria

Fit Score (1-10): - **Diagnostic Delay:** Does the condition experience >6 months average delay from symptom onset to diagnosis? - **Underdiagnosis:** Is >20% of prevalent population undiagnosed? - **Symptom Surfacing:** Can Ada's symptom checker realistically surface this condition from patient-reported symptoms? - **Per-Patient Revenue:** Does net revenue (post-rebate) exceed $50K/year? - **Addressable Funnel:** Is there a significant gap between total prevalence and diagnosed/treated population that Ada can bridge?

Revenue Assumptions: - **US Commercial:** Gross-to-net 40-60% (payers, rebates, discounts) - **EU/Ex-US:** Gross-to-net 15-25% (reference pricing, tender systems)

Product 1: Keytruda (pembrolizumab)

Fit Score: 5/10 (Marginal fit for specific indications)

Approved Indications: 40+ FDA approvals across NSCLC, melanoma, TNBC, head & neck, renal cell carcinoma, bladder, etc.[73][74]

Diagnostic Delay & Underdiagnosis Analysis by Indication:

Non-Small Cell Lung Cancer (NSCLC)

- **Prevalence:** ~77-85% of 235,000 annual U.S. lung cancer cases = ~180,000-200,000 NSCLC cases/year[118][119]
- **Diagnostic Delay:** Lung cancer often diagnosed at late stages due to asymptomatic early disease; median delay from symptom onset to diagnosis not well-quantified but estimated 2-6 months for symptomatic patients
- **Underdiagnosis:** Not applicable (late-stage disease); early detection challenge is lack of symptoms, not underdiagnosis of symptomatic patients
- **Keytruda-Eligible Funnel:**
- Metastatic NSCLC with PD-L1 expression: ~40-50% of NSCLC (~80,000-100,000 patients)
- Adjuvant/neoadjuvant early-stage: ~30,000-40,000 patients (growing indication)
- **Ada Surfacing Potential: Limited**. Early NSCLC is asymptomatic; symptomatic NSCLC presents with persistent cough, hemoptysis, chest pain, weight loss - symptoms that prompt physician visits but may be misattributed to COPD, bronchitis, or other respiratory conditions initially. Ada could surface red flags (hemoptysis + weight loss + smoking history) but would not identify asymptomatic early-stage disease.

Per-Patient Revenue (Keytruda): - **US WAC:** ~$180,000/year (IV); ~$200,000/year (QLEX estimated) - **Net Revenue (US Commercial, 50% gross-to-net):** ~$90,000-100,000/patient/year - **Duration:** Typically 1-2 years (until progression or toxicity) - **Lifetime Value:** $90K-200K per patient

Assessment: NSCLC meets revenue threshold but **diagnostic delay is not the core issue** - it's asymptomatic early disease. Ada's value would be in triaging patients with concerning respiratory symptoms (hemoptysis, unexplained weight loss + chronic cough) for expedited imaging, but this is a smaller subset of lung cancer patients.

Triple-Negative Breast Cancer (TNBC)

- **Prevalence:** ~10-15% of ~300,000 annual U.S. breast cancer cases = ~30,000-45,000 TNBC cases/year
- **Diagnostic Delay: 9.9% of TNBC patients** experience diagnostic delay (vs. 2.7% for HR+/HER2-) due to false-negative imaging/assessments; mean delay 128 days in delayed cohort[120]
- **Underdiagnosis:** Not 20%+ underdiagnosed, but **higher-than-average delay** in subset
- **Keytruda-Eligible Funnel:**
- High-risk early-stage TNBC (neoadjuvant/adjuvant): ~15,000-20,000 patients/year
- **Ada Surfacing: Moderate Potential**. Breast lumps, skin changes, nipple discharge are symptoms patients report; Ada could flag dense breast tissue + palpable mass as requiring urgent biopsy rather than "probably benign" follow-up (BI-RADS 3), addressing the false-negative delay issue[120]

Per-Patient Revenue: - Similar to NSCLC (~$90K-100K net/year for 1-2 years)

Assessment: TNBC has documented diagnostic delay in 9.9% of cases, but absolute patient numbers (~3,000 delayed patients/year) are modest. Ada could add value in triaging suspicious breast symptoms for biopsy, but **fit score limited by small absolute numbers** and fact that most TNBC patients are diagnosed appropriately.

Renal Cell Carcinoma (RCC)

- **Prevalence:** ~80,450 new U.S. cases/year; 676,631 living with diagnosis (2022)[121]
- **Diagnostic Delay:** Limited data; **66% diagnosed at localized stage** (often incidental imaging findings), **15% at distant metastatic stage**[121]
- **Underdiagnosis:** Not well-quantified; many RCCs found incidentally on imaging for other reasons

- **Keytruda-Eligible:** Advanced/metastatic RCC (~12,000-15,000 new patients/year eligible for first-line Keytruda + Lenvima or Keytruda + axitinib combinations)
- **Ada Surfacing: Low**. RCC is often asymptomatic until advanced; classic triad (flank pain, hematuria, palpable mass) occurs in <10% of patients[121]. Ada could flag hematuria + flank pain as concerning, but most RCC patients lack symptoms.

Assessment: RCC does not meet diagnostic delay or underdiagnosis criteria for Ada. **Fit Score: 3/10** for Keytruda in RCC.

Melanoma

- **Prevalence:** ~100,000 new cases/year (U.S.)
- **Diagnostic Delay:** Dermatology referral delays common; median not well-quantified
- **Underdiagnosis:** Skin cancer awareness campaigns generally effective; underdiagnosis not documented at >20%
- **Ada Surfacing: Moderate**. Changing moles, asymmetry, border irregularity are surfaceable symptoms, but visual assessment (dermatoscope, biopsy) required for diagnosis
- **Fit Score:** 4/10 - marginal; revenue threshold met but diagnostic delay/underdiagnosis not severe

Overall Keytruda Assessment: - **Best Ada Fit:** TNBC (9.9% diagnostic delay) and NSCLC (late-stage symptom misattribution) - **Revenue:** Exceeds $50K/patient threshold across all indications - **Addressable Funnel (NSCLC Example):** - Total lung cancer prevalence: ~500,000 living with diagnosis - Undiagnosed (asymptomatic early-stage): Not applicable - these patients have no symptoms to report to Ada - Symptomatic but delayed diagnosis: ~5-10% of cases (~10,000-20,000 patients/year) - **Ada-Addressable:** Patients with hemoptysis, weight loss, persistent cough who haven't yet received imaging - estimated **5,000-10,000 patients/year** could benefit from expedited workup - **Fit Score Rationale (5/10):** Keytruda treats multiple cancers, but most lack the diagnostic delay/underdiagnosis characteristics ideal for Ada. TNBC shows 9.9% delay, and symptomatic NSCLC may benefit from red-flag triaging, but these are subsets of total Keytruda patient population.

Product 2: Winrevair (sotatercept) for Pulmonary Arterial Hypertension

Fit Score: 9/10 (Excellent Ada Fit)

Indication: Pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise ability, improve WHO FC, reduce clinical worsening[80]

Disease Epidemiology: - **Prevalence:** 15-50 per million adults in US/Europe; 12.4-268 per million globally (varies by diagnostic methods)[94][122] - **U.S. Population:** ~4,900-16,500 diagnosed PAH patients (assuming 15-50 per million of 330M population) - **Diagnosis Delay: ~2 years** from symptom onset to right heart catheterization (RHC) confirmation[94][122] - **Underdiagnosis:** Estimated **>50% of PAH cases undiagnosed** due to: - Nonspecific early symptoms (dyspnea on exertion, fatigue, chest pain, syncope) mimicking asthma, heart failure, anxiety[94][122] - Low clinician suspicion in primary care - Reliance on echocardiography (less precise than RHC gold standard) yielding lower prevalence estimates (1.6 vs. 3.7 per 100,000 with RHC)[94] - **True Prevalence (Estimated):** If 50%+ undiagnosed, total PAH population could be **30-100 per million** = 10,000-33,000 U.S. patients

Winrevair-Eligible Funnel: - **Total PAH Prevalence (estimated):** 10,000-33,000 patients - **Currently Diagnosed:** ~5,000-16,500 patients - **Undiagnosed: ~5,000-16,500 patients** (50% underdiagnosis assumption) - **Eligible for Winrevair:** WHO Functional Class II-IV PAH on background therapy; ~70-80% of diagnosed patients = **3,500-13,000 currently eligible** - **Ada-Addressable:** Undiagnosed patients with progressive dyspnea, fatigue, syncope who haven't received echocardiography or RHC = **5,000-16,500 patients**

Symptom Surfacing via Ada: - **Primary Symptoms:** Progressive dyspnea on exertion (initially subtle, worsening over months), fatigue, chest pain (atypical), lightheadedness/syncope, peripheral edema (late)[94][122] - **Ada Pattern Recognition:** Young-to-middle-aged adult (peak 50-60 years) with: - Progressive exertional dyspnea (without lung disease history) - Fatigue disproportionate to exertion - Syncope or near-syncope with exertion - Family history of PAH (if heritable

form, 20% of cases) - Female (70-80% of PAH patients)[94] - **Ada Differential:** Could flag PAH in top differentials for this constellation; recommend echocardiography → RHC referral

Per-Patient Revenue (Winrevair): - **US WAC:** ~$300,000/year (estimated based on orphan drug pricing) - **Net Revenue (US Commercial, 50% gross-to-net):** ~$150,000/patient/year - **Duration:** Chronic therapy (lifelong unless transplant) - **Lifetime Value:** $1.5-3 million per patient (10-20 year horizon)

Pitch Hook for Ada Partnership:

"Pulmonary arterial hypertension affects an estimated 10,000-33,000 Americans, but over 50% remain undiagnosed due to the condition's subtle, nonspecific early symptoms - progressive shortness of breath and fatigue that patients and physicians often misattribute to deconditioning, asthma, or anxiety. The average patient waits two years from symptom onset to diagnosis, by which time irreversible vascular remodeling has occurred. Ada's symptom assessment can identify the unique pattern of exertional dyspnea, unexplained fatigue, and syncope in young-to-middle-aged adults - particularly women - and flag PAH for echocardiography, potentially halving diagnostic delay and capturing 5,000-16,500 currently undiagnosed patients. With Winrevair's net revenue of ~$150,000/patient/year and lifelong treatment, each diagnosed patient represents $1.5-3 million in lifetime value. Early diagnosis not only drives Winrevair uptake but also improves patient outcomes: modern PAH therapies deliver 89-96% one-year survival when started early, versus rapid deterioration when diagnosed late."

Fit Score Rationale (9/10): - ✅ Diagnostic delay: 2 years average - ✅ Underdiagnosis: >50% - ✅ Symptom surfacing: Dyspnea + fatigue + syncope pattern distinctive - ✅ Per-patient revenue: $150K/year net, $1.5-3M lifetime - ✅ Addressable funnel: 5,000-16,500 undiagnosed patients - ⚠️ Small absolute numbers (vs. COPD, diabetes) limit total revenue impact

---

Product 3: Welireg (belzutifan) for von Hippel-Lindau Disease

Fit Score: 7/10 (Good Ada Fit for VHL; Limited for RCC)

Indications: 1. Von Hippel-Lindau (VHL) disease-associated tumors in adults 2. Advanced renal cell carcinoma (RCC) post-chemotherapy[90][91]

VHL Disease Analysis

Disease Epidemiology: - **Prevalence:** 1 in 36,000 to 1 in 53,000 individuals; annual birth incidence 1 in 27,300-36,000[123] - **U.S. Population:** ~6,200-9,200 VHL patients (330M population / 36,000-53,000) - **Diagnosis Delay:** Mean diagnosis age 26 years, but symptoms can appear from infancy to 60-70 years; delay variable depending on family history and surveillance[123] - **Underdiagnosis:** ~20% arise from de novo mutations without family history; these patients may face diagnostic delay until multiple tumors (retinal hemangioblastomas, CNS hemangioblastomas, RCC) manifest[123] - **Penetrance:** >90% by age 65; ~20% asymptomatic at age 60 without surveillance[123]

Welireg-Eligible Funnel (VHL Indication): - **Total VHL Prevalence:** ~6,200-9,200 patients - **Symptomatic with VHL-associated tumors:** ~70-80% (penetrance by typical diagnosis age) = **4,300-7,400 patients** - **Currently Diagnosed:** ~80% (20% de novo mutations may have delay) = **5,000-7,400 patients** - **Undiagnosed:** ~1,200-1,800 patients with de novo mutations presenting with unexplained retinal/CNS hemangioblastomas or early-onset RCC - **Eligible for Welireg:** Adults with progressive VHL tumors not requiring immediate surgery = **2,000-3,000 patients** (estimated) - **Ada-Addressable:** De novo VHL patients (no family history) presenting with vision changes (retinal hemangioblastoma), neurological symptoms (CNS hemangioblastoma), or kidney masses (RCC) before VHL diagnosis = **1,200-1,800 patients**

Symptom Surfacing via Ada: - **Initial Presentations:**[123] - Vision loss, floaters, retinal detachment (retinal hemangioblastoma, 45-59% prevalence, bilateral in many) - Headaches, vomiting, ataxia, weakness (CNS hemangioblastoma, 44-72% cerebellar, 13-59% spinal) - Hematuria, flank pain (RCC, 24-45% prevalence) - Hypertension (pheochromocytoma, 0-60% prevalence) - Hearing loss, tinnitus (endolymphatic sac tumors, up to 10%) - **Ada Pattern Recognition:** Young adult (20s-40s) with: - Multiple/bilateral retinal hemangioblastomas OR - CNS hemangioblastoma + renal cysts OR - Early-onset

clear cell RCC (<40 years) + family history of kidney cancer - **Ada Recommendation:** Flag VHL syndrome; recommend genetic testing and multi-organ screening (ophthalmology, brain/spine MRI, abdominal CT)

Per-Patient Revenue (Welireg for VHL): - **US WAC:** ~$250,000/year (estimated) - **Net Revenue (US Commercial, 50% gross-to-net):** ~$125,000/patient/year - **Duration:** Chronic therapy (until tumor progression requiring surgery or drug failure) - **Orphan Drug Exclusivity:** 7-year FDA exclusivity for VHL indication - **Lifetime Value:** $1-2 million per patient

Pitch Hook (VHL):

"Von Hippel-Lindau disease is a rare genetic condition affecting ~6,200-9,200 Americans, with 20% arising from de novo mutations without family history. These patients often experience diagnostic delays of several years as they present with seemingly unrelated symptoms: vision loss from retinal hemangioblastomas, headaches from cerebellar tumors, or kidney masses - before clinicians recognize the multi-organ tumor pattern indicating VHL syndrome. Ada can identify the constellation of bilateral retinal lesions in a young adult, early-onset renal cell carcinoma, or CNS hemangioblastoma, prompting genetic testing that expedites VHL diagnosis. Early identification allows surveillance of other organs (pancreas, adrenal glands) and timely Welireg initiation to slow tumor growth, preventing vision loss and the need for repeated brain surgeries. With Welireg's net revenue of ~$125,000/patient/year and chronic dosing, each diagnosed VHL patient represents $1-2 million lifetime value, and 1,200-1,800 currently undiagnosed or delayed de novo cases are addressable via Ada's symptom assessment."

Fit Score Rationale (VHL Indication: 7/10): - ✅ Diagnostic delay: Years for de novo mutation patients - ⚠️ Underdiagnosis: ~20% de novo (modest percentage but significant delay in this subset) - ✅ Symptom surfacing: Multi-organ tumor pattern (retinal + CNS + renal) distinctive - ✅ Per-patient revenue: $125K/year net, $1-2M lifetime - ✅ Addressable funnel: 1,200-1,800 undiagnosed de novo patients - ⚠️ Very small absolute numbers limit revenue scale

Advanced RCC Indication (Welireg)

- **Fit Score: 3/10** - RCC diagnosis delay not well-documented; most advanced RCC patients already in oncology care. Welireg is later-line therapy (post-chemotherapy), not first-line, so patient identification is medical oncologist-driven, not primary care/symptom-driven.

Product 4: Ohtuvayre (ensifentrine) for COPD

Fit Score: 8/10 (Strong Ada Fit)

Indication: COPD maintenance treatment in adults[26][87]

Disease Epidemiology: - **Prevalence (U.S.):** 18+ million adults with spirometry-confirmed airflow limitation consistent with COPD[95][124] - **Diagnosed:** ~8.5 million adults with physician diagnosis (2007-2010 data)[95] - **Underdiagnosis: 65-81% of spirometrically-confirmed COPD undiagnosed**; international studies show 81.4% undiagnosed overall, ranging from 50% (Lexington, KY) to 98.3% (Ile-Ife, Nigeria)[95][124] - **U.S. Undiagnosed:** ~10-12 million adults with COPD lack diagnosis - **Diagnostic Delay:** Two-thirds of patients with COPD symptoms unaware of diagnosis despite reporting respiratory symptoms[125] - **Contributing Factors:**[95][124][125] - Lack of spirometry (only 26.4% of at-risk adults report prior lung function test) - Symptom adaptation (patients minimize/underreport chronic cough, dyspnea) - Sex bias (women less likely to receive COPD diagnosis than men for same symptoms) - Never referred to pulmonologist (77% underdiagnosis in non-referred patients)

Ohtuvayre-Eligible Funnel: - **Total COPD Prevalence:** ~18 million (spirometry-confirmed) - **Currently Diagnosed:** ~8.5 million - **Undiagnosed: ~10 million** (55% underdiagnosis, conservative vs. 65-81% estimates) - **Symptomatic Undiagnosed:** ~7-8 million (three-quarters report symptoms but undiagnosed)[125] - **Eligible for Ohtuvayre (Maintenance Therapy):** COPD patients with moderate-to-severe symptoms; ~60% of diagnosed COPD = **5 million**

currently eligible among diagnosed - **Ada-Addressable:** Symptomatic undiagnosed patients with chronic cough, dyspnea, sputum production who haven't received spirometry = **7-8 million patients**

Symptom Surfacing via Ada: - **Classic COPD Symptoms:** - Chronic cough (daily for >3 months/year for 2+ years) - Dyspnea on exertion, progressive over years - Sputum production (chronic bronchitis phenotype) - Wheezing, chest tightness - Frequent respiratory infections - **Risk Factors:** - Smoking history (20+ pack-years) - Occupational exposures (dust, chemicals) - Age >40 years - **Ada Pattern Recognition:** Adult 40+ with: - Chronic daily cough + dyspnea + smoking history - Progressive exertional limitation over years - No prior spirometry or asthma diagnosis - **Ada Recommendation:** Flag moderate-to-high COPD probability; recommend spirometry referral to primary care or pulmonology

Per-Patient Revenue (Ohtuvayre): - **US WAC:** ~$8,000-12,000/year (estimated based on COPD inhaler pricing; exact WAC not disclosed) - **Net Revenue (US Commercial, 50% gross-to-net):** ~$4,000-6,000/patient/year - **Duration:** Chronic therapy (lifelong) - **Lifetime Value:** $50,000-100,000 per patient (10-15 year horizon)

Pitch Hook for Ada Partnership:

"Chronic obstructive pulmonary disease affects an estimated 18 million Americans, yet 65-81% of spirometrically-confirmed COPD cases remain undiagnosed - leaving 10-12 million people with untreated progressive lung disease. The primary barrier isn't complex pathology: it's that patients and physicians normalize chronic cough and shortness of breath as 'smoker's cough' or aging, and only 26% of at-risk adults have ever had spirometry to confirm diagnosis. Two-thirds of COPD patients report respiratory symptoms to their doctors, yet remain undiagnosed and untreated. Ada can disrupt this by identifying the signature pattern - daily cough for months, progressive dyspnea, and smoking history in adults over 40 - and recommend spirometry, cutting through decades of symptom minimization. With 7-8 million symptomatic but undiagnosed COPD patients addressable via symptom assessment, Ada could drive diagnosis of 100,000-500,000 patients annually, each representing Ohtuvayre lifetime value of $50,000-100,000. Ohtuvayre, as the first novel COPD maintenance mechanism in 20 years, is positioned to become the preferred therapy for newly diagnosed patients, and early diagnosis matters: identifying COPD before severe irreversible lung damage improves quality of life and reduces exacerbation-driven hospitalizations."

Fit Score Rationale (8/10): - ✅ **Diagnostic delay:** Years of symptomatic disease before diagnosis - ✅ **Underdiagnosis:** 65-81% of cases undiagnosed - ✅ **Symptom surfacing:** Chronic cough + dyspnea + smoking history highly specific - ⚠️ **Per-patient revenue:** $4,000-6,000/year net (below $50K threshold for annual revenue, but **lifetime value $50K-100K meets threshold**) - ✅ **Addressable funnel:** 7-8 million symptomatic undiagnosed patients - ⚠️ **Commercial challenge:** Ohtuvayre must displace entrenched triple therapy (Trelegy, Breztri); newly diagnosed patients are "clean slate" opportunity

---

Product 5: Gardasil 9 (HPV Vaccine)

Fit Score: 2/10 (Poor Ada Fit)

Indication: Prevention of HPV-related cancers and genital warts in individuals 9-45 years[76][77]

Why Low Fit: - **Preventive Vaccine:** Gardasil prevents future disease; it does not treat existing conditions - **No Diagnostic Delay:** Vaccination decision is based on age and risk factors, not symptom-driven diagnosis - **No Underdiagnosis:** Cervical cancer screening (Pap smear, HPV testing) is well-established; vaccination is separate from diagnosis - **Symptom Surfacing Not Applicable:** Genital warts or cervical dysplasia symptoms would prompt physician visit, but Ada's role would be triaging for STI screening, not identifying undiagnosed Gardasil-eligible patients

Potential Ada Role (Limited): - **Vaccination Reminders:** Ada could identify unvaccinated 9-26 year-olds (recommended age range) and recommend catch-up vaccination - **Adult Catch-Up (27-45):** FDA approved through age 45; Ada could flag unvaccinated adults with new sexual partners as candidates for shared decision-making on vaccination - **Lifetime Value:** $400-600 per vaccinated individual (2-3 dose series), not annual revenue

Fit Score Rationale (2/10): Preventive vaccines don't align with Ada Patient Finder's diagnostic delay model; Gardasil is public health/vaccination program opportunity, not patient identification play.

Product 6: Capvaxive (PCV21 Pneumococcal Vaccine)

Fit Score: 3/10 (Poor Ada Fit)

Indication: Prevention of pneumococcal disease in adults[84][85]

Why Low Fit: - **Preventive Vaccine:** Similar to Gardasil; prevents future pneumonia/bacteremia, doesn't treat diagnosed disease - **Vaccination Guidelines:** ACIP recommends pneumococcal vaccination at age 65+ or younger with risk factors (immunocompromise, chronic disease) - **No Diagnostic Delay for Vaccination Decision:** Age-based or risk-based, not symptom-driven - **Lifetime Value:** ~$200-300 per vaccinated adult (1-2 doses)

Potential Ada Role (Very Limited): - **Vaccination Gap Identification:** Adults 65+ or high-risk adults <65 who haven't received pneumococcal vaccine; Ada could prompt discussion with PCP - **Not Patient Finder Model:** No undiagnosed disease to surface

Fit Score Rationale (3/10): Preventive vaccine; Ada's value would be vaccination gap closure (public health), not diagnostic patient finding.

Pipeline Asset: MK-7240 (PRA023) for Inflammatory Bowel Disease

Fit Score: 6/10 (Moderate Ada Fit; IBD Diagnosis Delay Documented but Complex)

Indication: Ulcerative colitis and Crohn's disease (Phase 3)[27][28][99]

Disease Epidemiology: - **Prevalence (U.S.):** ~3.1 million adults with IBD (~1.3% of U.S. adults); ~1.6M Crohn's, ~1.5M ulcerative colitis - **Diagnosis Delay:** Studies show **6-12 month average delay** from symptom onset to IBD diagnosis, particularly for Crohn's disease (more variable presentation than UC) - **Underdiagnosis:** Limited data on underdiagnosis percentage; delays common in younger patients and those presenting to primary care vs. gastroenterology - **Contributing Factors:** - Nonspecific GI symptoms (diarrhea, abdominal pain) attributed to IBS, infections, or stress initially - Waxing/waning symptoms (Crohn's) delay recognition of chronic pattern - Stigma around bowel symptoms; patients delay reporting

MK-7240-Eligible Funnel: - **Total IBD Prevalence:** ~3.1 million - **Moderate-to-Severe Disease:** ~1.5-2 million (requiring advanced therapy beyond mesalamine) - **First-Line Biologic-Eligible:** ~500,000-750,000 (newly diagnosed or first advanced therapy) - **Ada-Addressable (Delayed Diagnosis):** Patients with chronic diarrhea (>4 weeks), blood in stool, nocturnal diarrhea, weight loss who haven't received colonoscopy = estimated **100,000-200,000 patients/year** with delayed IBD diagnosis

Symptom Surfacing via Ada: - **Crohn's Disease Red Flags:** - Chronic diarrhea (>4 weeks) + abdominal pain (often right lower quadrant) - Blood in stool (less common than UC) - Perianal disease (fistulas, abscesses) - Weight loss, fatigue, fever - Young adult onset (peak 15-35 years) - **Ulcerative Colitis Red Flags:** - Bloody diarrhea (hallmark symptom) - Urgency, tenesmus - Left-sided abdominal pain - Nocturnal diarrhea - **Ada Pattern Recognition:** Young adult with: - Chronic bloody diarrhea + urgency + nocturnal symptoms (UC pattern) - Chronic non-bloody diarrhea + RLQ pain + weight loss (Crohn's pattern) - Negative stool cultures (ruling out infection) - **Ada Recommendation:** Flag moderate-to-high IBD probability; recommend gastroenterology referral and colonoscopy

Per-Patient Revenue (MK-7240, estimated): - **Projected Pricing:** $50,000-80,000/year (based on comparable biologics: Humira, Stelara, Entyvio) - **Net Revenue (US Commercial, 50% gross-to-net):** ~$25,000-40,000/patient/year - **Duration:** Chronic therapy (years to decades) - **Lifetime Value:** $300,000-800,000 per patient

Challenges for Ada Fit: - **IBS Overlap:** Many patients with chronic diarrhea + abdominal pain have IBS, not IBD; specificity challenge for Ada - **Colonoscopy Required for Diagnosis:** Ada can triage, but definitive diagnosis requires endoscopy and biopsy - **Pediatric Onset:** ~25% of IBD diagnosed in childhood/adolescence; Ada's adult-focused platform may miss this cohort

Pitch Hook (if MK-7240 Approved):

"Inflammatory bowel disease affects 3.1 million Americans, yet patients with Crohn's disease experience an average 6-12 month delay from symptom onset to diagnosis as physicians initially attribute chronic diarrhea and abdominal pain to irritable bowel syndrome, infections, or stress. This delay allows untreated inflammation to progress, increasing risk of strictures, fistulas, and need for surgery. Ada can disrupt this pattern by identifying red-flag symptoms - bloody diarrhea, nocturnal diarrhea, unintentional weight loss, or perianal disease - that distinguish IBD from benign functional disorders, prompting expedited gastroenterology referral and colonoscopy. With an estimated 100,000-200,000 patients per year experiencing diagnostic delay, Ada could capture newly diagnosed IBD patients early in their disease course, when first-line biologics like MK-7240 offer the best chance of inducing remission and preventing complications. At $25,000-40,000 net revenue per patient per year and decades of chronic therapy, each patient represents $300,000-800,000 lifetime value."

Fit Score Rationale (6/10): - ✅ Diagnostic delay: 6-12 months average - ⚠️ Underdiagnosis: Not well-quantified at >20%, but delays common - ⚠️ Symptom surfacing: Bloody diarrhea + nocturnal symptoms specific, but IBS overlap reduces specificity - ✅ Per-patient revenue: $25,000-40,000/year net - ⚠️ Addressable funnel: 100,000-200,000 delayed diagnoses/year (moderate scale)

Summary Table: Ada Patient Finder Fit Scores

Product	Indication	Diagnostic Delay	Underdiagnosis Rate	Symptom Surfacing	Per-Patient Net Revenue/Year	Addressable Patients	Ada Fit Scor
Winrevair	Pulmonary arterial hypertension	**2 years**	**>50%**	**High** (dyspnea + syncope pattern)	**$150,000**	**5,000-16,500**	**9/10** ⭐
Ohtuvayre	COPD maintenance	**Years**	**65-81%**	**High** (chronic cough + dyspnea + smoking)	$4,000-6,000 ($50K-100K lifetime)	**7-8 million**	**8/10** ⭐
Welireg	von Hippel-Lindau disease	**Years (de novo)**	~20% de novo	**Moderate** (multi-organ tumors)	**$125,000**	**1,200-1,800**	**7/10**
MK-7240 (Pipeline)	Inflammatory bowel disease	**6-12 months**	Not well-quantified	**Moderate** (bloody diarrhea; IBS overlap)	**$25,000-40,000**	**100,000-200,000/year**	**6/10**
Keytruda	TNBC, NSCLC,	**Variable** (9.9%	**Not >20% overall**	**Moderate** (cancer	**$90,000-100,000**	**5,000-10,000/year**	**5/10**

Product	Indication	Diagnostic Delay	Underdiagnosis Rate	Symptom Surfacing	Per-Patient Net Revenue/Year	Addressable Patients	Ada Fit Scor
	others	TNBC delay)		symptoms)			
Capvaxive	Pneumococcal prevention	N/A (preventive)	N/A	N/A	$200-300 (lifetime)	N/A	**3/10**
Gardasil 9	HPV prevention	N/A (preventive)	N/A	N/A	$400-600 (lifetime)	N/A	**2/10**

Top Ada Partnership Opportunities:

1. **Winrevair (PAH):** Highest fit; rare disease with massive underdiagnosis (>50%), long diagnostic delay (2 years), distinctive symptom pattern, and premium pricing ($150K/year)
2. **Ohtuvayre (COPD):** Massive underdiagnosis (10M+ patients), clear symptom pattern, and chronic therapy; lower annual revenue but enormous patient pool
3. **Welireg (VHL):** Strong fit for rare disease with diagnostic delay, but small absolute numbers

---

References

1. Merck Company History - MatrixBCG. https://matrixbcg.com/blogs/brief-history/merck
2. DCF Modeling - Merck History. https://www.dcfmodeling.com/blogs/history/mrk-history-mission-ownership
3. Bullfincher - Merck Employee Count. http://bullfincher.io/companies/merck-co/number-of-employees
4. Stock Analysis - Merck Employees. https://stockanalysis.com/stocks/mrk/employees/
5. Merck Q4 2025 Earnings Presentation. https://www.merck.com/wp-content/uploads/sites/124/2026/02/4Q25-Merck-Earnings-Presentation.pdf
6. Merck Q4 2025 Financial Results. https://www.merck.com/stories/our-q4-and-full-year-2025-financial-results/
7. Merck 2025 Highlights. https://www.merck.com/news/merck-highlights-progress-advancing-broad-diverse-pipeline/
8. Trading Economics - Merck EBITDA. https://tradingeconomics.com/mrk:us:ebitda
9. Merck KGaA Q4 2025 Report. https://www.merckgroup.com/en/news/q4-2025-05-03-2026.html
10. Merck Fact Sheet. https://www.merck.com/media/company-fact-sheet/
11. Public.com - Merck Market Cap. https://public.com/stocks/mrk/market-cap
12. Stock Analysis - Merck Market Cap. https://stockanalysis.com/stocks/mrk/market-cap/
13. Merck Q4 2025 Prepared Remarks. https://www.merck.com/wp-content/uploads/sites/124/2026/02/4Q25-Merck-Prepared-Remarks.pdf
14. BioSpace - Keytruda Patent Extension. https://www.biospace.com/business/mercks-keytruda-likely-has-a-few-extra-years-of-dominance-with-billions-on-the-line
15. Proclinical - Top Drugs Patent Expiry. https://www.proclinical.com/blogs/2024-2/top-10-drugs-with-patents-due-to-expire-in-the-next-5-years
16. I-MAK - Keytruda QLEX Analysis. https://www.i-mak.org/2025/10/17/keytruda-qlex-wheres-the-invention/
17. Fortune - Merck $50B Blockbuster Pipeline. https://fortune.com/well/2025/02/04/merck-touts-new-blockbuster-drugs-50-billion-potential/
18. TIKR - Merck $70B Pipeline. https://www.tikr.com/blog/merck-stock-why-expect-a-50-upside-after-the-70-billion-pipeline-disclosure
19. National Today - Merck Human Health Reorganization. https://nationaltoday.com/us/nj/rahway/news/2026/02/23/merck-evolves-human-health-operating-structure/
20. Merck Personnel Page. https://www.merck.com/personnel/

21. Merck Q4 2025 Earnings Announcement. https://www.merck.com/wp-content/uploads/sites/124/2026/02/4Q25-Merck-Earnings-Announcement.pdf
22. TIKR - Merck 2026 Outlook. https://www.tikr.com/blog/merck-stock-heres-why-street-points-to-127-mean-target
23. Merck Q4 2025 Other Financial Disclosures. https://www.merck.com/wp-content/uploads/sites/124/2026/02/4Q25-Merck-Other-Financial-Disclosures.pdf
24. Drug Discovery Trends - Merck 2025 Pharma50. https://www.drugdiscoverytrends.com/2025-pharma50/merck-co/
25. Contract Pharma - Merck Q4 Growth. https://www.contractpharma.com/breaking-news/merck-4q-growth-driven-by-oncology-vaccines/
26. Pharmaceutical Technology - Merck Verona Pharma. https://www.pharmaceutical-technology.com/news/merck-verona-pharma-10bn/
27. Merck Prometheus Acquisition Announcement. https://www.merck.com/news/merck-strengthens-immunology-pipeline-with-acquisition-of-prometheus-biosciences-inc/
28. Merck Prometheus Completion. https://www.merck.com/news/merck-completes-acquisition-of-prometheus-biosciences-inc/
29. Merck Cidara Acquisition. https://www.merck.com/news/merck-to-acquire-cidara-therapeutics-inc-diversifying-its-portfolio-to-include-late-phase-antiviral-agent/
30. STAT News - Merck Cidara. https://www.statnews.com/2025/11/14/merck-acquire-cidara-therapeutics-influenza-prevention/
31. Merck EyeBio Acquisition. https://www.merck.com/news/merck-to-acquire-eyebio/
32. Ophthalmology Times - Merck EyeBio. https://www.ophthalmologytimes.com/view/merck-to-acquire-eyebio-for-upfront-payment-of-1-3-billion
33. Merck Daiichi Sankyo ADC Collaboration. https://www.merck.com/news/daiichi-sankyo-and-merck-announce-global-development-and-commercialization-collaboration-for-three-daiichi-sankyo-dxd-adcs/
34. American Pharmaceutical Review - Daiichi Merck. https://www.americanpharmaceuticalreview.com/1315-News/608038-Daiichi-Sankyo-and-Merck-Announce-Global-Development-and-Commercialization-Collaboration-for-Three-Daiichi-Sankyo-DXd-ADCs/
35. Merck Gardasil Decline. https://financialfreedomisajourney.com/merck-expects-portfolio-to-support-stronger-growth-in-2026-28-2025-11-6/
36. Scribd - Merck Gardasil Analysis. https://www.scribd.com/document/877558175/Merck-s-Keytruda-Patent-Loss-Gardasil-in-Focus-Equity-Outlook
37. Syneticx - Merck Pipeline. https://www.syneticx.com/blog/merck.html
38. Medicare Rights - IRA Drug Negotiation. https://www.medicarerights.org/medicare-watch/2023/06/08/merck-sues-in-longshot-bid-to-derail-medicare-drug-price-negotiation
39. Porters Five Force - Merck History. https://portersfiveforce.com/blogs/brief-history/merck
40. Wikipedia - Merck & Co. https://en.wikipedia.org/wiki/Merck_%26_Co.
41. MMM Online - Ken Frazier Timeline. https://www.mmm-online.com/home/channel/a-timeline-of-ken-fraziers-time-at-merck/
42. Merck - Frazier Retirement. https://www.merck.com/news/kenneth-c-frazier-to-retire-as-merck-ceo-board-elects-robert-m-davis-as-successor-frazier-to-continue-as-executive-chairman/
43. Fierce Pharma - Merck CEO Compensation 2021. https://www.fiercepharma.com/pharma/merck-paid-its-ceos-combined-299-million-2021-152-departing-frazier-and-137m-incoming-davis
44. Fintool - Robert Davis Bio. https://fintool.com/app/research/companies/MRK/people/robert-m-davis
45. ROI-NJ - Robert Davis Profile. https://www.roi-nj.com/2021/02/04/healthcare/next-up-a-quick-look-at-mercks-new-ceo-robert-davis/
46. CEO Roundtable - Robert Davis. https://ceoroundtable.heart.org/companies/merck-2/
47. Drug Discovery Trends - Winrevair. https://www.drugdiscoverytrends.com/2025-pharma50/merck-co/
48. Merck Verona Pharma Completion. https://www.merck.com/news/merck-completes-acquisition-of-verona-pharma/
49. Fintel - Merck Institutional Owners. https://fintel.io/so/us/mrk
50. Merck Board of Directors. https://www.merck.com/company-overview/leadership/board-of-directors/
51. Merck Leadership. https://www.merck.com/company-overview/leadership/

52. YouTube - Robert Davis Interview. https://www.youtube.com/watch?v=gHDkIk2zctc
53. Merck Caroline Litchfield Appointment. https://www.merck.com/news/merck-appoints-caroline-litchfield-chief-financial-officer/
54. The Key Executives - Caroline Litchfield. https://www.thekeyexecutives.com/2022/10/05/merck-insider-caroline-litchfield-lands-top-cfo-position/
55. BioSpace - Merck C-Suite Shuffle. https://www.biospace.com/merck-c-suite-shuffle-continues-ahead-of-ceo-ken-frazier-s-june-retirement
56. Merck 2025 Proxy Statement. https://www.merck.com/wp-content/uploads/sites/124/2025/04/2025-Merck-Proxy-Statement.pdf
57. Merck - Dean Y. Li Bio. https://www.merck.com/leadership/dean-y-li/
58. Fintool - Dean Li. https://fintool.com/app/research/companies/MRK/people/dean-li
59. Merck - Jannie Oosthuizen Bio. https://www.merck.com/leadership/jannie-oosthuizen/
60. BioSpace - Merck Oncology Unit. https://www.biocentury.com/article/658514/merck-names-oosthuizen-head-of-new-cancer-unit
61. Contract Pharma - Merck Reorganization. https://www.contractpharma.com/breaking-news/merck-reorganizes-human-health-business-names-new-leadership/
62. Merck - Meet Our Scientists. https://www.merck.com/research/meet-our-scientists/
63. Merck Lenvima Partnership. https://www.merck.com/news/merck-and-astrazeneca-present-final-results-of-key-secondary-overall-survival-endpoint-from-phase-3-propel-trial-at-2023-american-society-of-clinical-oncology-genitourinary-cancers-symposium/
64. Fierce Pharma - Welireg Lenvima RCC. https://www.fiercepharma.com/pharma/merck-eyes-life-after-keytruda-loe-welireg-kidney-cancer-wins
65. Merck KEYNOTE-B96. https://www.merck.com/news/merck-announces-phase-3-keynote-b96-trial-met-secondary-endpoint-of-overall-survival-os-in-all-comers-population-of-patients-with-platinum-resistant-recurrent-ovarian-cancer/
66. Merck KEYLYNK-001. https://www.merck.com/news/merck-announces-phase-3-keylynk-001-trial-met-primary-endpoint-of-progression-free-survival-pfs-in-patients-with-advanced-epithelial-ovarian-cancer/
67. Merck ESMO 2025. https://www.merck.com/news/merck-advances-oncology-innovation-highlighting-progress-in-new-tumor-types-and-earlier-stages-of-disease-at-esmo-2025/
68. Merck Q4 2025 News Release. https://www.merck.com/wp-content/uploads/sites/124/2026/02/4Q25-Merck-Earnings-Announcement.pdf
69. Merck Q3 2025 News Release. https://www.merck.com/wp-content/uploads/sites/124/2025/10/Merck-News-Release-10-30-25-Merck-Co.-Inc.-Rahway-N.J.-USA-Announces-Third-Quarter-2025-Financial-Results.pdf
70. Merck Q3 2025 News Release. https://www.merck.com/wp-content/uploads/sites/124/2025/10/Merck-News-Release-10-30-25-Merck-Co.-Inc.-Rahway-N.J.-USA-Announces-Third-Quarter-2025-Financial-Results.pdf
71. Merck Q4 2025 Earnings Presentation (Keytruda Detail). https://www.merck.com/wp-content/uploads/sites/124/2026/02/4Q25-Merck-Earnings-Presentation.pdf
72. Merck ASCO GU 2026. https://www.merck.com/news/merck-advances-treatment-of-bladder-and-kidney-cancers-with-new-data-at-2026-asco-gu-cancers-symposium/
73. Keytruda HCP - Approved Indications. https://www.keytrudahcp.com/approved-indications/
74. FDA - Keytruda Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s180lbl.pdf
75. Nasdaq - Merck Competition. https://www.nasdaq.com/articles/merck-cancer-drug-powerhouse-could-be-core-dividend-holding-decades
76. FDA - Gardasil 9. https://www.fda.gov/vaccines-blood-biologics/vaccines/gardasil-9
77. Merck - Gardasil 9 Head/Neck Approval. https://www.merck.com/news/fda-approves-mercks-gardasil-9-for-the-prevention-of-certain-hpv-related-head-and-neck-cancers/
78. Drug Patent Watch - Gardasil Patents. https://www.drugpatentwatch.com/p/biologics/tradename/GARDASIL
79. Merck - Gardasil China Male Approval. https://www.merck.com/news/mercks-gardasil-receives-expanded-approval-for-males-in-china/
80. Drug Analyst - Winrevair Revenue. https://www.druganalyst.com/mrk/winrevair
81. Merck Q1 2025 Results. https://www.merck.com/news/merck-announces-first-quarter-2025-financial-results/

82. Merck Winrevair HYPERION. https://www.merck.com/news/winrevair-sotatercept-csrk-reduced-the-risk-of-clinical-worsening-events-by-76-compared-to-placebo-in-patients-recently-diagnosed-with-pah-on-background-therapy-in-phase-3-hyperion-trial/
83. Fierce Pharma - Winrevair Uptake 2025. https://www.fiercepharma.com/pharma/mercks-winrevair-poised-strong-uptake-2025-leerink
84. LifeSciVoice - Capvaxive Pediatric. https://lifescivoice.com/merck-capvaxive-children-results/
85. Vax Before Travel - Capvaxive. https://www.vax-before-travel.com/vaccines/capvaxive-pneumococcal-conjugate-vaccine
86. Mordor Intelligence - Pneumococcal Vaccine Market. https://www.mordorintelligence.com/industry-reports/pneumococcal-vaccines-market
87. Merck Q4 2025 Prepared Remarks (Ohtuvayre). https://www.merck.com/wp-content/uploads/sites/124/2026/02/4Q25-Merck-Prepared-Remarks.pdf
88. STAT News - Merck Verona. https://www.statnews.com/2025/07/09/merck-verona-pharma-lung-disease-keytruda-patent-protection-losses/
89. GenEng News - Patent Cliff 2026-2029. https://www.genengnews.com/topics/drug-discovery/top-20-drugs-heading-for-the-patent-cliff-2026-2029/
90. Drug Analyst - Welireg. https://www.druganalyst.com/mrk/welireg/
91. MSD - Merck Q2 2025 Welireg. https://www.msd.com/news/merck-co-inc-rahway-n-j-usa-announces-second-quarter-2025-financial-results/
92. YouTube - Merck Q4 2025 Earnings Call. https://www.youtube.com/watch?v=5lvegZmqOvg
93. Merck Q4 2025 Earnings Call Event. https://www.merck.com/events/q4-2025-earnings-call/
94. Rare Disease Advisor - PAH Epidemiology. https://www.rarediseaseadvisor.com/disease-info-pages/pulmonary-arterial-hypertension-epidemiology/
95. ATS Journals - COPD Underdiagnosis. https://www.atsjournals.org/doi/full/10.1164/rccm.201804-0621CI
96. Pharmalive - Merck Reorganization. https://www.pharmalive.com/merck-reorganizes-human-health-business-establishes-separate-oncology-business-unit/
97. Merck Canada Leadership. https://www.merck.ca/en/comp-overview/our-leadership-team/
98. Merck Executive Team. https://www.merck.com/company-overview/leadership/executive-team/
99. Syneticx - Merck Pipeline Deep Dive. https://www.syneticx.com/blog/merck.html
100. Merck Product Pipeline. https://www.merck.com/research/product-pipeline/
101. BiopharmaDive - Merck Daiichi Withdraw FDA. https://www.biopharmadive.com/news/merck-daiichi-withdraw-fda-application-lung-cancer-patritumab-deruxtecan/749243/
102. Fierce Biotech - I-DXd Partial Hold. https://www.fiercebiotech.com/biotech/patient-deaths-prompt-partial-hold-daiichi-mercks-global-phase-3-adc-program
103. BiopharmaDive - Merck Cidara Flu. https://www.biopharmadive.com/news/merck-cidara-acquire-flu-antiviral-drug/805513/
104. Glance Eyecare - Merck EyeBio. https://glance.eyesoneyecare.com/stories/2024-07-17/merck-officially-enters-ophthalmic-space-with-eyebio-acquisition/
105. Merck Welireg Lenvima Press. https://www.merck.com/news/merck-and-astrazeneca-present-final-results-of-key-secondary-overall-survival-endpoint-from-phase-3-propel-trial-at-2023-american-society-of-clinical-oncology-genitourinary-cancers-symposium/
106. Merck Daiichi MK-6070. https://www.merck.com/news/daiichi-sankyo-and-merck-enter-into-global-development-and-commercialization-agreement-for-mk-6070/
107. Statista - Merck Revenue by Region. https://www.statista.com/statistics/380844/revenues-of-merck-and-co-by-region/
108. UK MarketScreener - Merck Segments. https://uk.marketscreener.com/quote/stock/MERCK-CO-INC-119075588/finances-segments/
109. UK MarketScreener - Merck Geographic Data. https://uk.marketscreener.com/quote/stock/MERCK-CO-INC-119075588/finances-segments/
110. FirstWord Pharma - Keytruda Patent. https://firstwordpharma.com/story/7090843
111. MSD Japan - Welireg Approval. https://www.msd.com/news/merck-co-inc-rahway-n-j-usa-announces-second-quarter-2025-financial-results/

112. Markets FinancialContent - Merck Execution. https://markets.financialcontent.com/wral/article/marketminute-2026-1-15-the-execution-engine-how-merck-is-dominating-the